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PREFACE 
The VA Evidence Synthesis Program (ESP) was established in 2007 to provide timely and 
accurate syntheses of targeted healthcare topics of importance to clinicians, managers, and 
policymakers as they work to improve the health and healthcare of Veterans. These reports help:  
• Develop clinical policies informed by evidence; 
• Implement effective services to improve patient outcomes and to support VA clinical 
practice guidelines and performance measures; and  
• Set the direction for future research to address gaps in clinical knowledge. 
The program is composed of three ESP Centers across the US and a Coordinating Center located 
in Portland, Oregon. Center Directors are VA clinicians and recognized leaders in the field of 
evidence synthesis with close ties to the AHRQ Evidence-based Practice Center Program and 
Cochrane Collaboration. The Coordinating Center was created to manage program operations, 
ensure methodological consistency and quality of products, and interface with stakeholders. To 
ensure responsiveness to the needs of decision-makers, the program is governed by a Steering 
Committee composed of health system leadership and researchers. The program solicits 
nominations for review topics several times a year via the program website.  
Comments on this evidence report are welcome and can be sent to Nicole Floyd, Deputy 
Director, ESP Coordinating Center at Nicole.Floyd@va.gov. 
 
Recommended citation: Anderson J, Parr NJ, Vela K. Evidence Brief: Transcranial Magnetic 
Stimulation (TMS) for Chronic Pain, PTSD, TBI, Opioid Addiction, and Sexual Trauma. VA ESP 
Project #09-009; 2020. Posted final reports are located on the ESP search page. 
 
This report is based on research conducted by the Evidence Synthesis Program (ESP) Center located at 
the ESP Coordinating Center, Portland, OR, funded by the Department of Veterans Affairs, Veterans 
Health Administration, Health Services Research and Development. The findings and conclusions in this 
document are those of the author(s) who are responsible for its contents; the findings and conclusions do 
not necessarily represent the views of the Department of Veterans Affairs or the United States government. 
Therefore, no statement in this article should be construed as an official position of the Department of 
Veterans Affairs. No investigators have any affiliations or financial involvement (eg, employment, 
consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or 
pending, or royalties) that conflict with material presented in the report. 
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Transcranial magnetic stimulation (TMS) is a noninvasive therapy that 
uses coils to pass magnetic pulses through the skull to induce electrical 
currents. These currents stimulate the underlying brain cortex. TMS 
therapy can vary based on the types of coils used, the brain area 
stimulated, the frequency and intensity of the magnetic pulses, and the 
number and speed of pulses delivered. The most common therapeutic 
use of TMS is for treatment of major depressive disorder (MDD), and 
the FDA began approving various devices for this application in 2008.  
Since approval for MDD, TMS has been investigated for treatment of 
other conditions, including traumatic brain injury (TBI), post-traumatic 
stress disorder (PTSD), pain, schizophrenia, dementia, and substance 
use disorder. Compared to MDD, fewer studies have examined the 
efficacy of TMS for these conditions, and there remain open questions 
about the generalizability of existing evidence, the reliability of 
treatment effects, and the optimal treatment protocol for each 
condition.  
Based on evidence from 39 included controlled studies, our review 
suggests that repetitive TMS (rTMS), the most common form of TMS 
therapy, may be effective for treating chronic pain, PTSD, TBI, and 
opiate addiction (Table ES-1). However, there were inconsistent 
findings among studies, and about half of included studies found that 
reduction in chronic pain, PTSD, and TBI symptoms did not 
significantly differ between TMS therapy and sham therapy control 
groups. No studies specifically examined TMS as a therapy for sexual 
trauma, and no studies directly compared rTMS to novel forms of TMS 
such as theta-burst or electroencephalogram (EEG)-guided TMS. 
Key Findings 
• Most studies of transcranial magnetic stimulation (TMS) 
therapy employed repetitive TMS (rTMS). rTMS may 
reduce symptoms in people with chronic pain, post-
traumatic stress disorder (PTSD), traumatic brain injury 
(TBI), and opiate addiction, but findings are mixed among 
included studies. 
• rTMS could be a treatment option for patients who have 
exhausted other available options for treatment of chronic 
pain, PTSD, TBI, opiate addiction, but practical aspects of 
more widely implementing TMS in a healthcare system 
need to be considered.  
• Future research should focus on studies with larger 
samples, robust methodology, and standardized TMS 
parameters.  
Purpose 
The ESP Coordinating 
Center is responding to a 
request from the Center 
for Compassionate Care 
Innovation for an 
evidence brief on the use 
of transcranial magnetic 
stimulation (TMS) for 
the treatment of mental 
and physical health 
diagnoses (not including 
major depressive 
disorder). Findings from 
this evidence brief will 
be used to inform a 
VHA pilot program to 
provide access to TMS 
for Veterans suffering 
from chronic pain, post-
traumatic stress disorder 
(PTSD), traumatic brain 
injury (TBI), opioid 
addiction, or sexual 
trauma as required by 
HR 1162, “No Hero Left 
Untreated Act”. The 
goal of this review is to 
synthesize important and 
recent evidence on TMS 
effectiveness and safety 
for treatment of chronic 
pain, PTSD, TBI, opioid 
addiction, and sexual 
trauma.  
Methods 
To identify studies, we 
searched MEDLINE®, 
Cochrane Database of 
Systematic Reviews, 
Cochrane Central 
Register of Controlled 
Trials, and other sources 
up to August 2020. We 
used prespecified criteria 
for study selection, data 
abstraction, and rating 
internal validity and 
strength of the evidence. 
See our PROSPERO 
protocol for our full 
methods.  
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Despite the mixed effectiveness findings, TMS was found to be a safe and generally well-
tolerated therapy. 
There was considerable variation in patient populations (demographics, disease or symptom 
characteristics, etc), TMS protocols (TMS coil type and position, stimulation parameters, etc), 
and study methodology (sample size, outcomes and number of timepoints assessed, etc), among 
the included studies. This variation may contribute to the inconsistency in the observed effects of 
TMS therapy. Moreover, the generally small sample sizes of studies could have limited statistical 
power to detect differences between TMS and control conditions.  
Practical aspects of more widely implementing TMS in a health care system need further 
consideration, particularly as they relate to patient and provider burden, cost, and accessibility. 
TMS therapy generally consists of daily therapy, usually for a period of 4 to 6 weeks, and 
patients must travel daily to a designated clinic where TMS is offered. TMS therapy also requires 
assessment by a trained physician to determine if TMS therapy is appropriate and to prescribe 
the therapy. Limitations in transportation or clinic access for patients, staff availability, training 
requirements, and the need for a designated clinic site with TMS technology may be barriers in 
expanding use of TMS. 
Pairing these considerations with the findings that suggest potential effectiveness and high 
patient safety and acceptability, it is reasonable to conclude that TMS therapy, in particular 
rTMS, could be considered a treatment option for patients who have exhausted other available 
options for treatment of chronic pain, PTSD, TBI, or opiate addiction. With this approach, a 
limited expansion of rTMS could be conducted, which would provide additional information 
about implementation feasibility and would allow for more rigorous trials to be conducted.  
Table ES-1. Summary of Findings 
Condition Evidence Summary 
Chronic Pain 17 controlled studies 
14 rTMS, 3 iTBS 
Low to Moderate SOE 
rTMS and iTBS may reduce pain, but inconsistent 
findings among studies 
PTSD 10 RCTs 
8 rTMS, 1 iTBS, 1 sTMS 
Low SOE 
rTMS and sTMS may reduce PTSD symptoms, but 
inconsistent findings among studies  
TBI 10 controlled studies* 
Low SOE 
rTMS may improve symptoms after TBI, but 
inconsistent findings among studies 
Opiate Addiction 2 RCTs* 
Moderate SOE 
rTMS likely improves opiate craving in adults with 
heroin addiction 
Sexual Trauma 0 studies – 
*All included studies examined rTMS
Abbreviations: rTMS=repetitive transcranial magnetic stimulation; iTBS=intermittent theta-burst TMS;
SOE=strength of evidence; PTSD=post-traumatic stress disorder; RCT=randomized controlled trial;
sTMS=synchronized TMS; TBI=traumatic brain injury





The ESP Coordinating Center (ESP CC) is responding to a request from the Center for 
Compassionate Care Innovation for an evidence brief on the use of transcranial magnetic 
stimulation (TMS) for the treatment of mental and physical health diagnoses (not including 
major depressive disorder). Findings from this evidence brief will be used to inform a VHA pilot 
program to provide access to TMS for Veterans suffering from chronic pain, post-traumatic 
stress disorder (PTSD), traumatic brain injury (TBI), opioid addiction, or sexual trauma as 
required by HR 1162, “No Hero Left Untreated Act”.1  
BACKGROUND 
What is Transcranial Magnetic Stimulation? 
TMS is a noninvasive therapy that uses magnetic pulses to induce electrical currents in various 
parts of the brain.2 TMS was introduced in 1985,3 and has been used in a variety of applications, 
including for intraoperative neurologic monitoring,4 to investigate nerve conduction, to diagnose 
neurologic conditions,5 and for the treatment of psychiatric and neurologic conditions. 
Therapeutic use of TMS involves placing an insulated coil over various areas of the scalp and 
passing magnetic pulses through the skull and into the brain.6 The exact biological mechanism of 
TMS is unknown, but it is hypothesized that as magnetic pulses pass through the skull, electrical 
activity is induced in nerve cells, activating underlying areas of the brain cortex.3,7 This induced 
activity may alter synaptic plasticity, or the ability of nerve cell connections to strengthen or 
weaken over time.8 Biological studies have shown changes in neural activity with TMS 
treatment, including increased blood flow and dopamine transmission in areas of the brain 
targeted by TMS.3 
TMS therapy can vary based on the types of coils used, the brain area stimulated, the frequency 
and intensity of the magnetic pulses, and the number and speed of pulses delivered. Depending 
on the type of coil used, magnetic pulses can be delivered over large regions or more focused 
areas of the brain. The most common coil types are circular coils, figure-8 coils, and H-coils.9 
The multiple layers of coils inside the H-coil helmet allow for deeper stimulation (~4 cm) into 
the brain compared to conventional circular or figure-8 coils, which can stimulate about 1 cm 
into the brain.10 Additionally, different areas of the brain can be targeted by placing the coil over 
different locations of the scalp. Common locations for stimulation include the primary motor 
cortex and dorsolateral prefrontal cortex (DLPFC), with variation in placement over the right 
hemisphere, left hemisphere, or midline.11,12  
The magnetic pulses during TMS therapy can be delivered at different frequencies (measured in 
Hertz [Hz]) and intensities. Low frequency (< 5 Hz) stimulation has inhibitory effects on neural 
activity in the brain, while high frequency ( ≥ 5 Hz) stimulation has excitatory effects.9 The 
intensity of TMS therapy is often individualized, and is set at a proportion of an individual’s 
motor threshold (described as the strength of stimulus required to produce movement of the 
thumb or fingers). Intensities set at more than 100% of this threshold may have greater risk of 
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adverse events, including seizure.3 However, typically MDD TMS protocols treat at 100-120% 
of RMT without significant side effects in most patients.13 TMS therapy can also vary based on 
the number and duration of magnetic pulses delivered. Repetitive TMS (rTMS) delivers 
magnetic pulses to the brain rapidly at regular intervals and is the most widely studied and 
commonly used type of TMS. Alternatively, TMS can be delivered as a single pulse, where 1 
pulse occurs no faster than once every few seconds.14 
Novel TMS therapies proposed to enhance the therapeutic effect of TMS include theta-burst 
TMS (iTBS), synchronized TMS (sTMS), and electroencephalogram (EEG)-guided TMS. Theta-
burst TMS delivers either an intermittent or continuous triple-pulse magnetic stimulation, which 
is hypothesized to induce longer-lasting therapeutic effects. It is delivered at a higher frequency 
(~50 Hz) than rTMS (~5-10 Hz) and requires shorter TMS sessions (~3 minutes vs ~20-30 
minutes). In synchronized TMS, magnetic fields are synchronized to a person’s intrinsic alpha 
frequency using multiple magnets. EEG-guided TMS involves placing the TMS coil over an 
EEG cap so that brain activity can be measured during TMS therapy, allowing for real-time 
assessment of the optimal TMS parameters.5 Another form of EEG-guided TMS, Magnetic 
eResonance Therapy (MeRTSM),15 involves recording and analyzing a patient’s EEG at various 
time points during the course of treatment to develop a tailored TMS treatment plan. It is unclear 
whether these forms of TMS offer improved outcomes over rTMS. 
Therapeutic Uses for Transcranial Magnetic Stimulation 
The most common therapeutic use of TMS is for treatment of depression. In 2008, the first rTMS 
device for treatment of major depressive disorder (MDD) was approved by the FDA,16 and 
several other devices have since been cleared for this use.17 Numerous studies have shown 
benefits of rTMS therapy in patients with depression, including decreases in depression symptom 
severity, and greater response and remission rates among patients with the use of rTMS 
compared to sham TMS.7,18 There are various treatment protocols for rTMS for depression, but a 
typical protocol may be daily (5 days/week) 20 to 40 minute rTMS sessions over a period of 4 to 
8 weeks, with each session delivering 3,000 to 6,000 pulses at 10 Hz.3 The American Psychiatric 
Association and National Network of Depression Centers rTMS Task Group issued guidance for 
clinicians to help navigate the variety of rTMS protocols available for the treatment of 
depression.13 This guidance outlines recommendations for coil selection and placement, 
magnetic field intensity and frequency (Hz), and number and duration of pulses. Additionally, it 
is recommended to assess patients for risk factors, including history of stroke or seizure, alcohol 
and drug use, sleep deprivation, and any side effects of previous rTMS use, prior to 
implementing rTMS and again at each session.13 
Since approval for MDD, rTMS has been investigated for treatment of other conditions, 
including TBI,19-21 PTSD,22-27 pain,28,29 schizophrenia,24,30 dementia,22 and substance use 
disorder.22,31,32 The FDA expanded the approved marketing of rTMS for treatment of certain 
headaches in 2013 and for obsessive-compulsive disorder (OCD) in 2018.17 Compared with 
MDD, fewer studies have examined the efficacy of TMS for these conditions, and there remain 
open questions about the generalizability of existing evidence, the reliability of treatment effects, 
and the optimal treatment protocol for each condition. 
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Usage of TMS in the VHA 
TMS therapy in the VHA is offered through the National Clinical rTMS program, which began 
in 2017 as an effort to expand access to rTMS therapy for Veterans.33 There are currently 35 VA 
rTMS clinics across the US, with additional clinics under development. Currently, rTMS is most 
commonly used within the VHA for treatment of depression, and the VA/DoD guideline for 
major depressive disorder recommends offering rTMS during a major depressive episode in 
patients with treatment-resistant MDD.34 There is interest in expanding the use of TMS to treat 
other conditions, including TBI, PTSD, chronic pain, opioid addiction, and sexual trauma, but 
the evidence on the use of TMS therapy for these conditions among Veterans is less established. 
VA/DoD guidelines for PTSD,34 mild TBI (tinnitus after mild TBI, update in progress),34 and 
headache34 state that there is insufficient evidence to recommend for or against the use of rTMS 
for treatment of these conditions (supplemental materials Appendix A).  
The goal of this evidence brief is to synthesize important and recent evidence on TMS 
effectiveness and safety for treatment of chronic pain, PTSD, TBI, opioid addiction, and sexual 
trauma. The review is intended to inform development of a TMS program for treatment of 
Veterans with these conditions.  
KEY QUESTIONS 
Key Question 1: What is the effectiveness of TMS for the treatment of post-traumatic stress 
disorder, traumatic brain injury, sexual trauma, chronic pain, or opioid addiction?  
Key Question 2: What are the potential adverse effects of using TMS for the treatment of post-
traumatic stress disorder, traumatic brain injury, sexual trauma, chronic pain, or opioid 
addiction?  
Key Question 3: Do the effectiveness and potential adverse effects of TMS differ according to 
patient or intervention characteristics (eg, patient demographics, comorbidities, disease severity, 
TMS frequency)? 
ELIGIBILITY CRITERIA 
The ESP included studies that met the following criteria: 
Population: Adults with post-traumatic stress disorder, traumatic brain injury, sexual trauma, 
chronic pain, or opioid addiction  
• Intervention: Transcranial magnetic stimulation (eg, repetitive, theta-burst, EEG-guided, 
EKG-guided, or combination EEG/EKG guided) 
• Comparator: Any 
• Outcomes: Symptom improvement (eg, response, remission), mortality, quality of life, 
adverse events (eg, headache, worsening symptoms, nausea, seizure) 
• Timing: Any 
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• Setting: Any 
• Study design: Using a best-evidence approach, we will prioritize evidence from 
systematic reviews and multisite comparative studies that adequately controlled for 
potential patient-, provider-, and system-level confounding factors. Inferior study designs 
(eg, single-site, inadequate control for confounding, noncomparative) will only be 
accepted to fill gaps in higher-level evidence
Evidence Brief: TMS for Conditions other than Depression Evidence Synthesis Program 
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METHODS 
DATA SOURCES AND SEARCHES 
To identify articles relevant to the key questions, our research librarian searched MEDLINE 
(Ovid), CINAHL (EBSCO), PsycINFO (Ovid), and CENTRAL (Ovid) databases as well as 
AHRQ, CADTH, Cochrane, VA HSR&D, and Clinicaltrials.gov websites using terms for 
transcranial magnetic stimulation, post-traumatic stress disorder, traumatic brain injury, opioid 
disorders, and sexual trauma from January 2012 to August 2020. We located an existing 
systematic review on TMS and chronic pain35 with an end search date in 2017, so we searched 
the same databases using terms for transcranial magnetic stimulation and chronic pain from 
January 2017 to August 2020 (see Appendix B in supplemental materials for full search 
strategies). Because of the large number of citations for chronic pain, we excluded pain areas that 
were of low interest to the report nominators (bladder pain, hemiplegic shoulder pain, and 
orofacial pain). Additional citations were identified from hand-searching reference lists and 
consultation with content experts. We limited the search to published and indexed articles 
involving human subjects available in the English language. Study selection was based on the 
eligibility criteria described above. Titles and abstracts and full-text articles were reviewed by 1 
reviewer and checked by another. All disagreements were resolved by consensus or discussion 
with a third reviewer. 
DATA ABSTRACTION AND QUALITY ASSESSMENT 
We used predefined criteria to rate the internal validity of all controlled studies. We used 
Cochrane’s Risk of Bias Tools to rate the internal validity of systematic reviews and 
concurrently controlled studies.36-38 We abstracted data from all included studies and results for 
each included outcome. All data abstraction and internal validity ratings were first completed by 
1 reviewer and then checked by another. All disagreements were resolved by consensus. 
SYNTHESIS 
Strength of evidence (SOE) grading was based on the AHRQ Methods Guide for Comparative 
Effectiveness Reviews,39 by considering risk of bias (includes study design and aggregate 
quality), consistency, directness, and precision of the evidence. Ratings typically range from high 
to very low, indicating our confidence that the evidence reflects an unbiased and precise estimate 
of the true effect. For this review, we applied the following general algorithm: evidence 
composed of multiple, large studies with low risk of bias were rated as “high strength” evidence, 
evidence composed of multiple studies with low to unclear risk of bias and consistent findings 
were rated as “moderate strength”, evidence composed of single studies, or multiple small 
studies with unclear to high risk of bias and/or inconsistent findings were rated as “low strength”, 
and evidence composed of a single study with high risk of bias was rated as “very low strength”. 
These criteria were applied to primary outcomes for all conditions. Because quality of life was 
inconsistently reported as a primary or secondary outcome in TBI-related studies, strength of 
evidence was evaluated for any quality of life outcome reported by these studies. Strength of 
evidence ratings were completed by 1 reviewer and checked by another. We synthesized the 
evidence qualitatively by condition, prioritizing controlled studies.  
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A draft version of this report was reviewed by peer reviewers as well as clinical leadership (see 
supplemental materials for disposition of peer review comments). The complete description of 
our full methods can be found on the PROSPERO international prospective register of 
systematic reviews (http://www.crd.york.ac.uk/PROSPERO/; registration number 
CRD42020202648). 




The literature flow diagram (Figure 1) summarizes the results of the study selection process (full 
list of excluded studies available in supplemental materials, Appendix C).  
Figure 1: Literature Flowchart 
 
Records identified through database searching 
n=2,438 
 
Medline = 1,215 
PsychINFO = 471 
CCRCT = 509 
CINAHL = 243 
 
Records identified through 
reference lists and grey 
literature searching 
n=54 
Records remaining after 
removal of duplicates 
n=1,729 
 
Records remaining after title 
and abstract review 
n=154 
 
Records remaining after full-





39 controlled studies 





-Ineligible population n=10 
-Ineligible intervention n=5 
-Ineligible outcome n=6 
-Ineligible study design n=3 
-Ineligible publication type n=40 
-Non-prioritized SR n=29 
-Ineligible language n=1 

























*In 56 publications (1 study with 2 publications) 
CCRCT=Cochrane Register of Controlled Trials, CINAHL=Cumulative Index to Nursing and Allied Health 
Literature, SR = systematic review 
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Our search identified 1,729 potentially relevant articles. We included 55 studies: 1 systematic 
review (see Appendix D in supplemental materials for primary studies included in this review),35 
39 controlled studies (in 40 publications),40-79 and 15 case series.80-94 The majority of the 
controlled studies were in populations with chronic pain (n = 17), PTSD (n = 10), or TBI (n = 
10). Two studies were identified in patients with opiate addiction,71,95 and no studies were 
identified in patients with sexual trauma. We also identified 39 ongoing studies (see Appendix E 
in supplemental materials for details), 13 for chronic pain, 7 for PTSD, 5 for TBI, and 14 for 
opiate addiction. Most studies investigated rTMS (N=34), but several studies examined use of 
intermittent theta-burst stimulation (iTBS)54,70,48,67 or synchronized TMS (sTMS)65 (Figure 2).  
Figure 2. Overview of Included Controlled Studies 
 
Abbreviations: rTMS=repetitive TMS; PTSD=post-traumatic stress disorder; TBI=traumatic brain injury, 
iTBS=intermittent theta-burst TMS; sTMS=synchronized TMS 
Most of the included controlled studies were RCTs (N=34), with follow-up ranging from 1 week 
to 7 months (Table 1). TMS protocols varied widely by TMS target location, frequency and 
intensity of stimulation, and number and duration of sessions (for full study details see Appendix 
F in supplemental materials). Sham TMS most often consisted of a “sham coil” which mimicked 
the vibrations and sounds of the TMS coil, or placement of the TMS coil at 90° away from the 
skull.  
Most studies had unclear risk of bias (N=24) (supplemental materials, Appendix G) and common 
study limitations were unclear or inappropriate handling of missing outcome data, lack of 
reporting of study follow-up or withdrawal, unclear allocation concealment, and self-reported 
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outcomes (Figure 3). Self-reported outcomes were considered a potential risk of bias, given that 
self-reporting may be subject to bias and is unblinded by definition. However, because most 
outcomes assessed in the primary studies were, by necessity, self-reported (eg, change in severity 
of pain, opiate cravings, or PTSD symptoms), use of self-reported measures was not considered 
sufficient to increase the overall risk rating of studies (eg, from low to unclear overall risk).  
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Left or right 
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1 Hz (right), 10 
Hz (left) 
110% RMT 
20 sessions (over 4 wks) 














Right DLPFC 1 Hz 
100% RMT 
10 (5 consecutive 





Veterans with mild TBI 
and post-traumatic 
headache 














Veterans with mild TBI 
related headache 














People with severe TBI 
and prolonged coma  










People with chronic TBI rTMS Change in 
executive 
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Left DLPFC 10 Hz 
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Right DLPFC 1 Hz110% RMT 20 (5 consecutive 





People with TBI and 
TRD 





Left and right 
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10 (5 consecutive 






Male heroin use 
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Subjective 0-
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Left DLPFC 10 Hz or 1 Hz 
100% RMT 





Heroin addicted adults rTMS Craving score: 
Subjective 0-
100 scale 
Left DLPFC 10 Hz 
100% RMT 
5 sessions (daily) 
*Petrosino, 2020 and Philip, 2019 are two reports of the same study.
Abbreviations: TMS=Transcranial magnetic stimulation; RCT= Randomized controlled  trial; rTMS=Repetitive transcranial magnetic stimulation; Hz=Hertz; RMT=Resting
motor threshold;  ACC=Anterior cingulate cortex; PSI=Posterior superior insula; nRCT=non-randomized controlled trial, DLPFC=Dorsolateral prefrontal cortex; CNP =Central
neuropathic pain; iTBS=Intermittent theta-burst stimulation, SCI=Spinal cord injury; MDD=Major depressive disorder;  TRD=Treatment resistant depression; wk/wks =
week/weeks
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Figure 3. Risk of Bias in Included Randomized Controlled Trials 
 
CHRONIC PAIN 
Overall Pain Reduction 
A 2018 Cochrane systematic review35 examined the use of non-invasive brain stimulation 
therapies for chronic pain. Forty-two studies on the effect of rTMS for pain were included. These 
studies measured pain severity using visual analog scales (VAS) or numerical rating scales 
(NRS). Overall, meta-analyses showed a significant reduction in pain associated with rTMS 
within 7 days post-intervention (SMD = -0.22, 95% CI [-0.29, -0.16]; 27 studies). Reductions in 
pain were also observed between 1 and 6 weeks post-intervention (SMD = -0.28, 95% CI [-0.61, 
0.05]; 11 studies) and at greater than 6 weeks post-intervention (SMD = -0.14, 95% CI [-0.44, 
0.17]; 4 studies), but these effects were nonsignificant. Significant improvement in reported 
quality of life (Fibromyalgia Impact Questionnaire) was observed within 7 days post-
intervention (SMD = -10.8, 95% CI [-15.04, -6.55]; 4 studies). Minor and brief-duration adverse 
effects were commonly reported across studies and included headache, pain at stimulation site, 
and dizziness. Studies varied by type of pain conditions included and rTMS protocols used. 
Study quality was rated mostly as “unclear” and was limited by unclear blinding of participants 
(inadequate sham), small sample size, and short study duration.  
Our search identified 17 controlled studies published since the end search date of this systematic 
review.35 Findings from these studies are discussed by pain type, below. 
Neuropathic Pain 
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rTMS therapy may reduce pain (measured by VAS or NRS) in patients with neuropathic pain, 
but the evidence is limited by inconsistent findings, and unclear or lack of blinding of patients or 
outcome assessors, and unclear or inadequate handling of missing data in several studies. Among 
8 controlled trials, 5 studies43,54,68,72,79 reported reduction in pain with TMS compared to sham 
TMS, while 3 studies41,49,51 reported no significant difference in pain between TMS and sham 
groups. In the 2 largest trials (N=100;49 N=14451), no significant difference was found between 
rTMS and sham groups in pain reduction. Most studies reported shorter-term outcomes (1 to 6 
weeks), but 3 studies reported outcomes at 3 to 7 months (1 study no pain reduction,49 2 studies 
pain reduction68,72 compared to sham). A single study compared iTBS to sham iTBS,54 and all 
other studies utilized rTMS. Studies varied with respect to pain areas (upper limb, lower limb, 
central neuropathic pain, etc), types of TMS (2 studies deep TMS,49,72 1 study intermittent theta-
burst TMS54) and TMS protocols (target location, frequency, intensity, and number of sessions). 
Evidence from 3 case series88,89,92 generally agreed with trial findings, indicating reductions in 
pain over time with TMS therapy. 
Fibromyalgia 
 
In patients with fibromyalgia syndrome, rTMS therapy may be no better than sham rTMS 
therapy in reducing overall pain symptoms (measured by VAS or NRS).42,44,45,76,50,77 This 
evidence is limited by small sample sizes (4 of 6 studies had 30 or fewer participants) and lack of 
or inadequate randomization in several studies. Six controlled studies reported reduction in pain 
outcomes in both rTMS and sham rTMS groups, with generally no significant differences in 
outcomes between groups. However, several studies reported greater reduction of pain with 
rTMS therapy for specific rTMS target locations (reduction in pain with primary motor cortex vs 
sham but not left DLPFC vs sham),42 time points (reduction in pain with rTMS compared to 
sham at week 2 vs week 1, but no significant difference when comparing weekly pain scores),45 
or outcomes (more patients achieving 30% reduction in pain in TMS group compared to sham 
group, but no significant difference in average pain reduction between groups).77 Most studies 
reported shorter-term outcomes (2 to 6 weeks), with the exception of 1 study reporting no 
significant reduction in pain at 6 months compared to control.50 All studies used rTMS and 
targeted either the primary motor cortex42,50 or the left DLPFC42,44,45,77 with 10 Hz stimulation at 
80-100% RMT, but the number and duration of TMS sessions varied among the studies. 
Headache 
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TMS therapy likely reduces headache pain and symptoms compared to sham TMS in patients 
with chronic headache or migraine,63,70  but the evidence is limited by small sample sizes, and 
non-random allocation and unclear handling of missing data in 1 study.70 Two studies reported 
decreases in pain (using NRS)63 or migraine frequency, severity, and duration70 at 8 to 12 weeks 
with rTMS therapy targeted to the right DLPFC63 or iTBS therapy targeted to the left DLPFC70 
compared to sham.  
Multiple or Other Pain Conditions 
A single small cohort study and several case series examined multiple or other pain conditions. 
The cohort study48 reported reductions in pain (measured by VAS and NRS) in patients with 
complex regional pain syndrome with both 1 or 5 sessions of iTBS stimulation immediately 
followed by rTMS, with no differences between groups. Since all patients in this study received 
some type of TMS stimulation, it is not possible to determine the effectiveness of TMS 
compared to sham. Three case series reported reductions in pelvic pain91,93 and general pain 
(from multiple conditions)90 over time with TMS therapy. These studies are limited by a study 
design without a control group. 
POST TRAUMATIC STRESS DISORDER 
 
rTMS therapy may improve PTSD symptoms compared to sham, but evidence is limited by 
inconsistent findings and methodological limitations, including unclear or inappropriate handling 
of missing data, differential attrition between intervention groups, and unclear blinding in several 
studies. Among 10 controlled studies (in 11 publications),40,47,53,55,56,64-67,75,58 most studies 
reported improvements in PTSD symptoms, as measured by the Clinician-Administered PTSD 
Scale (CAPS) or the PTSD Checklist (PCL). However, only 4 studies reported greater 
improvement in symptoms with TMS compared to sham. Among included studies, TMS 
protocols varied in target location, frequency, intensity, and number of sessions. 
One study40 reported a greater proportion of responders (defined as 2 or more standard deviations 
from the mean PCL score) with rTMS compared to sham, but no significant difference in mean 
PCL improvement between groups. Six studies were in Veterans with PTSD,40,47,53,55,56,67 the 
largest of which (N=113)55 reported improved PTSD symptoms at 6 months with rTMS therapy 
compared to control. Only 2 other studies reported outcomes beyond 8 weeks, and these studies 
found no significant difference in PTSD symptoms at 3 months compared to control.56,58 Two 
studies compared different frequencies of rTMS stimulation: 1 study55 found improved CAPS 
score with both 1 Hz and 10 Hz stimulation, but no significant difference between groups, while 
another study58 found improved CAPS score with 1 Hz rTMS compared to sham, but not with 10 
Hz rTMS compared to sham. Several case series80,82,84-87,94 generally agreed with findings of 
randomized trials, reporting improvements in PTSD symptoms with rTMS therapy over time. 
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Two RCTs examined the effect of theta-burst TMS (iTBS)65,67 or synchronized TMS (sTMS),66 
and found no significant differences between groups on PCL or CAPS scores at 2 to 4 weeks 
following treatment. In the study of sTMS, however, significantly fewer PCL items (symptoms) 
were rated as moderate or higher severity among participants receiving sTMS compared to sham 
4 weeks post-treatment. The iTBS study also examined clinical relapse – defined as suicide 
attempt, suicide-related death, inpatient psychiatric hospitalization, or need for retreatment with 
rTMS – at 1 year and found that fewer patients had clinical relapse with iTBS compared to 
sham.65 One case series82 examined EEG-guided magnetic resonance therapy (MeRTSM) and 
reported improvement in PTSD symptoms after treatment. We also identified 1 RCT (abstract 
only)96 that reported improvement in PTSD symptoms in 8 subjects with use of MeRTSM, but 
there was no significant difference in outcomes between MeRTSM and sham therapy.  
TRAUMATIC BRAIN INJURY 
 
rTMS therapy may improve symptoms after TBI, but evidence is limited by inconsistent 
findings, small sample sizes, and unclear blinding of outcome assessors and unclear or 
inadequate handling of missing data in several studies. TBI can result in lasting cognitive 
sequelae, mood sequelae, and other symptoms, and we included any study that examined the 
effects of TMS on any symptom subsequent to any severity (mild, moderate, or severe) TBI. 
Included studies reported on a variety of symptoms following TBI, including pain, depressive 
symptoms, headache, and executive function. Most studies included patients with mild to 
moderate TBI,46,57,59,60,69,73,74 but 3 studies52,62,78 included patients with severe TBI exclusively or 
along with other TBI severity levels. 
rTMS therapy improved headache symptoms,60,74,83 and overall pain (using NRS)46 compared to 
sham therapy in patients with TBI. Two studies in Veterans60,83 reported improvement in 
headache symptoms after mild TBI at 4 weeks with rTMS compared to sham therapy, while 
another study reported no significant difference in headache symptoms with rTMS after mild 
TBI compared to sham therapy at 6 months in a sample of patients from Canada.74 Four 
studies52,57,69,73 reported improved depressive symptoms with rTMS therapy after mild to 
moderate TBI, but there were no significant differences between rTMS and sham therapy in 3 of 
the 4 studies. One study69 reported no significant difference in rates of depression response or 
remission after mild to moderate TBI between rTMS and sham groups.  
Seven studies examined the effect of rTMS therapy on executive function in patients after mild 
to severe TBI.52,57,60,69,74,78,83 Most studies found some improvement in function, but only 2 
studies reported differences between rTMS and sham groups.57,83 Several studies46,62,74 also 
examined the effect of rTMS on quality of life. Most studies reported improvements in quality of 
life overall, but only one study reported significant differences between rTMS and sham 
therapy.62  
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Most studies reported outcomes at 2 to 6 weeks, but 3 studies reported no significant difference 
in TBI symptoms at 3 to 6 months compared to control.69,74,78 All studies examined rTMS, but 
varied in target location, frequency, intensity, and number of sessions. Two case series81,83 
generally agreed with these findings, reporting improvements in post-concussive symptoms and 
pain with rTMS therapy over time. 
OPIATE ADDICTION 
 
In adults with heroin addiction, rTMS therapy likely improves craving scores compared to sham 
therapy.61,71 Only 2 studies examined the effectiveness of rTMS for opiate use, and these studies 
are limited by unclear blinding of outcome assessors and/or participants and unclear handling of 
missing data. Both studies reported decreases in craving scores (0 to 100 craving scale) with 
rTMS therapy targeting the left DLPFC at 10 Hz and 100% resting motor threshold compared to 
sham rTMS. These studies assessed rTMS effects at different timepoints, ranging from 5 days 
after treatment71 to 90 days after treatment.61 
ADVERSE EFFECTS OF TMS 
TMS therapy appears to be well-tolerated among patients with chronic pain, PTSD, TBI, and 
opiate addiction. About half of the included studies reported mild side effects including 
headache, nausea, pain at the target location, and dizziness, and 8 studies40,48,55,56,58,61,68,69 
reported withdrawal of a small number of patients from the study due to side effects. No serious 
adverse events were reported in any included studies.
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SUMMARY AND DISCUSSION 
rTMS therapy is widely used for treatment of MDD, and there is interest in expanding its use for 
other conditions including chronic pain, PTSD, TBI, opiate addiction, and sexual trauma. Our 
review of recent studies and systematic reviews suggests that rTMS therapy may be effective for 
treating chronic pain, PTSD, TBI, and opiate addiction. Importantly, however, about half of 
controlled studies examining the efficacy of TMS for reducing symptoms of chronic pain, PTSD, 
and TBI found that reduction in symptoms did not significantly differ between TMS and control 
groups (sham TMS). The majority of studies utilized rTMS, with few studies examining novel 
forms of TMS (eg, iTBS, sTMS, or EEG-guided TMS) and no studies directly compared rTMS 
to other forms of TMS.  
Most studies examined differences in mean changes in outcome scores, which may yield 
statistically significant findings, but the magnitude of the difference may not translate into a 
clinically meaningful outcome for the patient. The 3 studies56,69,77 which examined symptom 
response or remission reported no significant difference between treatment and control groups in 
fibromyalgia pain,77 PTSD,56 or TBI69 symptom response or remission. Further, only 2 studies 
evaluated the efficacy of rTMS for opiate addiction,61,71 and no studies specifically examined 
TMS as a therapy for sexual trauma. Some patients with PTSD may have experienced sexual 
trauma, but less than half (4 of 10) of the included studies in patients with PTSD reported trauma 
history. Among these, only 2 studies listed patients with sexual trauma (range: 10 to 52% of 
patients). Further research on effectiveness of TMS among persons who have experienced sexual 
trauma, regardless of whether they have received a PTSD diagnosis, is needed. 
In addition to these mixed or limited findings, there was considerable variation in patient 
populations, outcomes assessed, and TMS protocols implemented among the included studies. 
As a result, the effectiveness of TMS therapy may vary by patient factors (age, sex, sleep 
deprivation, etc) and technical factors (TMS coil type and position, stimulation parameters, 
etc).97 Reviewed studies also varied methodologically (eg, sample size, outcomes and number of 
timepoints assessed, etc), which could contribute to the inconsistency in the observed effects of 
TMS therapy. Moreover, the generally small sample sizes of studies could have limited statistical 
power to detect differences between TMS and control conditions. Despite the mixed 
effectiveness findings, TMS was found to be a safe and well-tolerated therapy.  
Practical aspects of more widely implementing TMS in a healthcare system need further 
consideration, particularly as they relate to patient and provider burden, cost, and accessibility. 
TMS therapy generally consists of daily therapy, usually for a period of 4 to 6 weeks, and 
patients must travel daily to a designated clinic where TMS is offered. This may present 
challenges for Veterans living in rural areas or for those with transportation limitations. Although 
TMS therapy can be provided by a trained technician, a physician must perform a formal 
assessment to determine if TMS therapy is appropriate, followed by a prescription for the 
therapy. Limitations in staff availability, training requirements, and the need for a designated 
clinic site with TMS technology may be barriers in expanding the use of TMS. 
Pairing these considerations with the findings that suggest potential effectiveness and high 
patient safety and acceptability, it is reasonable to conclude that TMS therapy, in particular 
rTMS, could be considered a treatment option for patients who have exhausted other available 
options for treatment of chronic pain, PTSD, TBI, and opiate addiction. A limited expansion of 
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TMS for this purpose would provide further information about TMS implementation feasibility, 
while allowing additional efficacy and effectiveness trials to be conducted.  
LIMITATIONS  
The evidence included in this review has several important limitations. Studies were mostly 
small, and varied in patient populations, outcomes, and TMS protocols, making generalizations 
of findings across studies difficult. Studies were also inconsistent in their methodological quality 
and findings, resulting in mostly low strength of evidence for the effect of TMS on chronic pain, 
PTSD, TBI, and opiate addiction (Table 2, Appendix H in supplemental materials). Additionally, 
although several studies followed patients for up to 7 months, most studies assessed outcomes at 
only 1 to 4 weeks. Without longer follow-up periods, the durability of symptom improvement 
following TMS remains unclear. Finally, no studies were found that specifically examined the 
effect of TMS among individuals who experienced sexual trauma or that examined differential 
effects of TMS among those with PTSD and sexual trauma compared to those with PTSD and 
other trauma history. 
Limitations of our review methods include restricting our literature search date for chronic pain 
to the end search date of the O’Connell 201835 review. Additionally, we used a second reviewer 
check during study selection, data abstraction, and quality assessment rather than dual 
independent review.  
Table 2. Evidence Summary 
Outcome Studies (N) Strength of Evidence (SOE) Summary 
Chronic Pain: Neuropathic 
Pain 8 RCTs (N=420) 
7 rTMS,41,43,49,51,68,72,79  
1 iTBS54 
Low SOE 
rTMS may decrease pain compared to sham, but confidence is 
limited by inconsistent findings and low to high RoB among 
studies. 
Chronic Pain: Fibromyalgia* 
Pain 5 RCTs 




rTMS may be no better than sham in decreasing pain 
compared to sham, but confidence is limited by small sample 
sizes and low to high RoB among studies. 




2 RCTs (N=71) 
1 rTMS,63 1 iTBS70 
Moderate SOE 
TMS likely decreases headache pain and symptoms compared 
to sham but confidence is limited by small sample size and low 




10 RCTs (N=383)  
8 rTMS,40,47,53,55,56,58,64,75  
1 iTBS,67 1 sTMS66 
Low SOE 
rTMS may improve PTSD symptoms compared to sham, but 
confidence is limited by inconsistent findings and low to high 
RoB among studies. 
Clinical 
relapse** 
1 RCT (N=46), iTBS65 Low SOE 
iTBS may improve clinical relapse compared to sham, but 
confidence is limited by a single study. 
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Outcome Studies (N) Strength of Evidence (SOE) Summary 
TBI* 
Pain 1 RCTs (N=12)46 Low SOE 
rTMS may improve pain compared to sham, but confidence is 
limited confidence by a single, small study with unclear RoB. 
Depression 
symptoms 
4 RCTs (N=83)52,57,69,73 Low SOE 
rTMS may improve depressive symptoms compared to sham, 
but confidence is limited by inconsistent findings and unclear 
RoB among studies. 
Headache 
symptoms 
3 RCTs (N=73)60,74,83 Low SOE 
rTMS may improve headache symptoms compared to sham, 
but confidence is limited by inconsistent findings and low to 
unclear RoB among studies. 
Quality of 
Life 
2 RCTs46,74 (N=32) and 
1 nRCT (N=12)62  
Low SOE 
It is unclear whether rTMS improves quality of life in patients 
with TBI, and confidence is limited by inconsistent findings and 
low to high RoB among studies 
Function 7 RCTs 
(N=177)52,57,60,69,74,78,83 
Low SOE 
It is unclear whether rTMS improves function in patients with 
TBI, and confidence is limited by inconsistent findings and 




2 RCTs (N=138)61,71 Moderate SOE 
rTMS likely improves craving scores in opiate addicted adults 
compared to sham, but confidence is limited by unclear RoB 
among studies. 
1 cohort study, Gaertner 2018, examined iTBS for chronic regional pain syndrome, not included in table 
*All studies examined rTMS 
**Defined as suicide attempt, suicide-related death, inpatient psychiatric hospitalization, or need for rTMS 
retreatment 
Abbreviations: SOE= Strength of Evidence, RCT= Randomized controlled trial, rTMS=Repetitive transcranial 
magnetic stimulation, iTBS= Intermittent theta-burst stimulation, RoB=Risk of Bias, nRCT=non-randomized 
controlled trial, PTSD=Post traumatic stress disorder, sTMS=Synchronized TMS; TBI=Traumatic brain injury 
GAPS AND FUTURE RESEARCH 
Findings of this review suggest that it would be premature to conclude that TMS is an effective 
therapy for chronic pain, PTSD, TBI, and opiate addiction among Veteran populations. 
Additional studies with larger samples, robust methodology (ie, appropriate randomization and 
matching procedures), and standardized TMS parameters (ie, following various TMS guidance 
for specific patient populations, if available)98 are needed to provide more conclusive evidence. 
To address limitations to the existing evidence on the effectiveness of TMS for conditions other 
than MDD, future studies should consider the following: 
• Although many RCTs were identified, most were small. This may be an inherent 
limitation to studies due to the cost of neurotherapies. However, greater resource 
investment would be beneficial to clarify the effectiveness of TMS for chronic pain, 
PTSD, TBI, and opiate addiction. 
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• No studies examined the use of TMS specifically for sexual trauma, and studies in this 
area are needed to determine the effectiveness of TMS therapy among individuals who 
have experienced sexual trauma. 
• Studies directly comparing novel TMS therapy such as theta-burst or EEG-guided TMS 
to rTMS are needed to determine if these therapies offer any advantage over rTMS. 
 
CONCLUSIONS 
rTMS therapy may reduce symptoms in people with chronic pain, PTSD, TBI, and opiate 
addiction and could be a treatment option for patients who have exhausted all other available 
options. However, findings are mixed and there is wide variability in patient and intervention 
characteristics among the included studies. Future research should focus on studies with larger 
samples, robust methodology, standardized TMS parameters, and direct comparisons of rTMS to 
novel TMS therapies (eg, iTBS, sTMS, or EEG-guided TMS). Practical aspects of more widely 
implementing TMS in a health care system, including patient and provider burden, cost, and 
accessibility, also need further consideration.  
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APPENDIX A: VA/DOD GUIDELINES 
Year Title Condition TMS-related guidance 
2017 Management of 
Posttraumatic Stress 




There is insufficient evidence to recommend 
for or against the following somatic therapies: 
repetitive transcranial magnetic stimulation 
(rTMS), electroconvulsive therapy (ECT), 
hyperbaric oxygen therapy (HBOT), stellate 
ganglion block (SGB), or vagal nerve 
stimulation (VNS). 
2020 The Primary Care 
Management of Headache 
Headache There is insufficient evidence to recommend 
for or against the following for headache: 
•Transcranial magnetic stimulation 
•Transcranial direct current stimulation 
•External trigeminal nerve stimulation 
•Supraorbital electrical stimulation 
2016 Management of Concussion-





There is no evidence to suggest for or against 
the use of any particular modality for the 
treatment (including rTMS) of tinnitus after 
mTBI. 
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APPENDIX B: SEARCHES 
1. Search for current systematic reviews (limited to last 7 years) 
Date Searched: 08-06-2020 
A. Bibliographic 
Databases:  














1946 to February 
05, 2020 
1 Transcranial Magnetic Stimulation/ 11013 
2 (transcranial magnetic stimulation$1 or rTMS or TMS).mp. 21201 
3 1 or 2 21201 
4 
(systematic review.ti. or meta-analysis.pt. or meta-analysis.ti. or 
systematic literature review.ti. or this systematic review.tw. or 
pooling project.tw. or (systematic review.ti,ab. and review.pt.) or 
meta synthesis.ti. or meta-analy*.ti. or integrative review.tw. or 
integrative research review.tw. or rapid review.tw. or umbrella 
review.tw. or consensus development conference.pt. or practice 
guideline.pt. or drug class reviews.ti. or cochrane database syst 
rev.jn. or acp journal club.jn. or health technol assess.jn. or evid 
rep technol assess summ.jn. or jbi database system rev 
implement rep.jn. or (clinical guideline and management).tw. or 
((evidence based.ti. or evidence-based medicine/ or best 
practice*.ti. or evidence synthesis.ti,ab.) and (((review.pt. or 
diseases category/ or behavior.mp.) and behavior mechanisms/) 
or therapeutics/ or evaluation studies.pt. or validation studies.pt. 
or guideline.pt. or pmcbook.mp.)) or (((systematic or 
systematically).tw. or critical.ti,ab. or study selection.tw. or 
((predetermined or inclusion) and criteri*).tw. or exclusion 
criteri*.tw. or main outcome measures.tw. or standard of care.tw. 
or standards of care.tw.) and ((survey or surveys).ti,ab. or 
overview*.tw. or review.ti,ab. or reviews.ti,ab. or search*.tw. or 
handsearch.tw. or analysis.ti. or critique.ti,ab. or appraisal.tw. or 
(reduction.tw. and (risk/ or risk.tw.) and (death or 
recurrence).mp.)) and ((literature or articles or publications or 
publication or bibliography or bibliographies or published).ti,ab. or 
pooled data.tw. or unpublished.tw. or citation.tw. or citations.tw. or 
database.ti,ab. or internet.ti,ab. or textbooks.ti,ab. or 
references.tw. or scales.tw. or papers.tw. or datasets.tw. or 
trials.ti,ab. or meta-analy*.tw. or (clinical and studies).ti,ab. or 
treatment outcome/ or treatment outcome.tw. or pmcbook.mp.))) 
not (letter or newspaper article).pt. 
382964 
5 3 and 4 717 
6 limit 5 to english language 686 








Reviews 2005 to 
February 4, 2020 
1 Transcranial Magnetic Stimulation/ 0 
2 (transcranial magnetic stimulation$1 or rTMS or TMS).mp. 68 
3 1 or 2 68 
4 limit 3 to last 7 years 
47 
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2. Search for systematic reviews currently under development (includes forthcoming reviews & 
protocols) 
Date Searched: 08-06-20 
D. Under 
development:  


























3. Search for primary literature 
Date searched: 08-15-20 
MEDLINE [Ovid MEDLINE(R) ALL 1946 to July 14, 2020] 
# Search Statement Results 
1 Transcranial Magnetic Stimulation/ 11396 
2 
(transcranial magnetic stimulation$1 or rTMS or TMS or (repetitive adj transcranial 
magnetic stimulation$1) or (single-pulse adj transcranial magnetic stimulation$1) or 
(paired?pulse adj transcranial magnetic stimulation$1)).ti,ab,kw. 
20349 
3 1 or 2 21918 
4 Chronic Pain/ 14451 
5 (chronic adj1 pain).ti,ab,kw. 36934 
6 4 or 5 43337 
7 3 and  6 246 
8 limit 7 to english language 236 
9 limit 8 to yr=”2017-Current” 77 
CINAHL [EBSCO] 
# Search Statement Results 
1 (MH "Transcranial Magnetic Stimulation")   1234 
2 
TI ( (transcranial magnetic stimulation# or rTMS or TMS or (repetitive N1 transcranial 
magnetic stimulation#) or (single-pulse N1 transcranial magnetic stimulation#) or (paired 
pulse N1 transcranial magnetic stimulation#)) ) OR AB ( (transcranial magnetic 
stimulation# or rTMS or TMS or (repetitive N1 transcranial magnetic stimulation#) or 
(single-pulse N1 transcranial magnetic stimulation#) or (paired?pulse N1 transcranial 
magnetic stimulation#)) )   
3637 
3 1 or 2 3896 
4 (MH "Chronic Pain") 23575 
5 TI (chronic N1 pain) OR AB (chronic N1 pain) 27466 
6 4 or 5 38370 
7 3 and 6 118 
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8 limit 7 to english language 116 
9 limit 8 to 2017-Current 30 
CCRCT [EBM Reviews - Cochrane Central Register of Controlled Trials June 2020] 
# Search Statement Results 
1 Transcranial Magnetic Stimulation/ 1360 
2 
(transcranial magnetic stimulation$1 or rTMS or TMS or (repetitive adj transcranial 
magnetic stimulation$1) or (single-pulse adj transcranial magnetic stimulation$1) or 
(paired?pulse adj transcranial magnetic stimulation$1)).ti,ab,kw. 
5643 
3 1 or 2 5823 
4 Chronic Pain/ 2241 
5 (chronic adj1 pain).ti,ab,kw. 8487 
6 4 or 5 9437 
7 3 and  6 139 
8 limit 7 to english language 90 
9 limit 8 to yr=”2017-Current” 37 
 
 
4. Search for primary literature - TMS-all + PTSD/TBI/Opioid addiction/MST 
Date searched: 08-10-20 
MEDLINE [Ovid MEDLINE(R) ALL 1946 to August 07, 2020] 
# Search Statement Results 
1 exp Transcranial Magnetic Stimulation/ or Magnetic Stimulation Therapy/ 12590 
2 
(TMS or ((transcrani* or crani* or brain*) adj4 (electrostim* or electro-stim* or 
electrotherap* or electro-therap*)) or electrical stimulation or electrical treatment or 
((brain* or cortex or cortical or transcranial* or cranial or magneti*) adj4 stimulat*) or 
(transcranial magnetic stimulation or rTMS or cranial electrostimulation or cranial 
electrotherapy)).ti,ab,kw. 
95929 
3 (MeRT or magnetic eResonance therapy or magnetic e-Resonance therapy).ti,ab,kw. 
268 
4 
(magnetic EEG?EKG guidance resonance therapy or magnetic EEG guided 
resonance therapy or magnetic EEG-guided resonance therapy or magnetic EKG-
guided resonance therapy or magnetic EKG-guided resonance therapy).ti,ab,kw. 
0 
5 
(EEG?EKG guided TMS or EEG guided TMS or EEG-guided TMS or EKG guided 
TMS or EKG-guided TMS or EEG guided transcranial magnetic stimulation or EEG-
guided transcranial magnetic stimulation or EKG guided transcranial magnetic 
stimulation or EKG guided transcranial magnetic stimulation or q-EEG or quantitative 
EEG).ti,ab,kw. 
1402 
6 or/1-5 99318 
7 Stress Disorders, Post-Traumatic/ or exp Brain Injuries, Traumatic/ or exp Opioid-Related Disorders/ or Sexual Harassment/ or exp Sex Offenses/ 
96630 
8 (PTSD or post-traumatic stress disorder or posttraumatic stress disorder or post-
traumatic stress disorders or posttraumatic stress disorders or post-traumatic 
neuroses or posttraumatic neuroses or moral injury or moral injuries).ti,ab,kw. 
34503 
9 (TBI or TBIs or traumatic brain injury or traumatic brain injuries or brain trauma or 
brain traumas or traumatic encephalopathy or traumatic encephalopathies).ti,ab,kw. 
44065 
10 (opioid related disorders or opioid-related disorders or opioid addiction or opioid 
addictions or opioid dependence or opioid dependences or opiate abuse or opiate 
abuses or opiate dependence or opiate addiction or opioid abuse or opioid 
abuses).ti,ab,kw. 
7202 
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11 ((sexual* adj1 (trauma or abuse or violence or harassment or assault or assults or 
assulted) or (sex* adj1 offense or offenses) or rape or raped)).ti,ab,kw. 
30052 
12 or/7-11 160123 
13 6 and 12 802 
14 limit 13 to english language 770 
15 limit 14 to yr=”2012-Current” 541 
CINAHL [EBSCO] 
# Search Statement Results 
1 (MH "Transcranial Magnetic Stimulation")   1215 
2 
TI ( (TMS or ((transcrani* or crani* or brain*) adj4 (electrostim* or electro-stim* or 
electrotherap* or electro-therap*)) or electrical stimulation or electrical treatment or 
((brain* or cortex or cortical or transcranial* or cranial or magneti*) adj4 stimulat*) or 
(transcranial magnetic stimulation or rTMS or cranial electrostimulation or cranial 
electrotherapy)) ) OR AB ((TMS or ((transcrani* or crani* or brain*) adj4 (electrostim* 
or electro-stim* or electrotherap* or electro-therap*)) or electrical stimulation or 
electrical treatment or ((brain* or cortex or cortical or transcranial* or cranial or 
magneti*) adj4 stimulat*) or (transcranial magnetic stimulation or rTMS or cranial 
electrostimulation or cranial electrotherapy)) ) OR SU ((TMS or ((transcrani* or crani* 
or brain*) adj4 (electrostim* or electro-stim* or electrotherap* or electro-therap*)) or 
electrical stimulation or electrical treatment or ((brain* or cortex or cortical or 
transcranial* or cranial or magneti*) adj4 stimulat*) or (transcranial magnetic 
stimulation or rTMS or cranial electrostimulation or cranial electrotherapy)) ) 
10359 
3 
TI ( (MeRT or magnetic eResonance therapy or magnetic e-Resonance therapy) ) 
OR AB ( (MeRT or magnetic eResonance therapy or magnetic e-Resonance 
therapy) ) OR SU ( (MeRT or magnetic eResonance therapy or magnetic e-
Resonance therapy) ) 
40 
4 
TI ( (magnetic EEG?EKG guidance resonance therapy or magnetic EEG guided 
resonance therapy or magnetic EEG-guided resonance therapy or magnetic EKG-
guided resonance therapy or magnetic EKG-guided resonance therapy) ) OR AB ( 
(magnetic EEG?EKG guidance resonance therapy or magnetic EEG guided 
resonance therapy or magnetic EEG-guided resonance therapy or magnetic EKG-
guided resonance therapy or magnetic EKG-guided resonance therapy) ) OR SU ( 
(magnetic EEG?EKG guidance resonance therapy or magnetic EEG guided 
resonance therapy or magnetic EEG-guided resonance therapy or magnetic EKG-
guided resonance therapy or magnetic EKG-guided resonance therapy) ) 
0 
5 
TI ( (EEG?EKG guided TMS or EEG guided TMS or EEG-guided TMS or EKG 
guided TMS or EKG-guided TMS or EEG guided transcranial magnetic stimulation or 
EEG-guided transcranial magnetic stimulation or EKG guided transcranial magnetic 
stimulation or EKG guided transcranial magnetic stimulation or q-EEG or quantitative 
EEG) ) OR AB ( (EEG?EKG guided TMS or EEG guided TMS or EEG-guided TMS 
or EKG guided TMS or EKG-guided TMS or EEG guided transcranial magnetic 
stimulation or EEG-guided transcranial magnetic stimulation or EKG guided 
transcranial magnetic stimulation or EKG guided transcranial magnetic stimulation or 
q-EEG or quantitative EEG) ) OR SU ( (EEG?EKG guided TMS or EEG guided TMS 
or EEG-guided TMS or EKG guided TMS or EKG-guided TMS or EEG guided 
transcranial magnetic stimulation or EEG-guided transcranial magnetic stimulation or 
EKG guided transcranial magnetic stimulation or EKG guided transcranial magnetic 
stimulation or q-EEG or quantitative EEG) ) 
226 
6 S1 OR S2 OR S3 OR S4 OR S5 10622 
7 (MH "Stress Disorders, Post-Traumatic+") OR (MH "Brain Injuries+") OR (MH "Sexual Harassment") OR (MH "Substance Use Disorders+") 214680 
8 TI ( (PTSD or post-traumatic stress disorder or posttraumatic stress disorder or post-traumatic stress disorders or posttraumatic stress disorders or post-traumatic 16203 
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neuroses or posttraumatic neuroses or moral injury or moral injuries) ) OR AB ( 
(PTSD or post-traumatic stress disorder or posttraumatic stress disorder or post-
traumatic stress disorders or posttraumatic stress disorders or post-traumatic 
neuroses or posttraumatic neuroses or moral injury or moral injuries) ) OR SU ( 
(PTSD or post-traumatic stress disorder or posttraumatic stress disorder or post-
traumatic stress disorders or posttraumatic stress disorders or post-traumatic 
neuroses or posttraumatic neuroses or moral injury or moral injuries) ) 
9 
TI ( (TBI or TBIs or traumatic brain injury or traumatic brain injuries or brain trauma or 
brain traumas or traumatic encephalopathy or traumatic encephalopathies) ) OR AB ( 
(TBI or TBIs or traumatic brain injury or traumatic brain injuries or brain trauma or 
brain traumas or traumatic encephalopathy or traumatic encephalopathies) ) OR SU 
( (TBI or TBIs or traumatic brain injury or traumatic brain injuries or brain trauma or 
brain traumas or traumatic encephalopathy or traumatic encephalopathies) ) 
17087 
10 
TI ( (opioid related disorders or opioid-related disorders or opioid addiction or opioid 
addictions or opioid dependence or opioid dependences or opiate abuse or opiate 
abuses or opiate dependence or opiate addiction or opioid abuse or opioid abuses) ) 
OR AB ( (opioid related disorders or opioid-related disorders or opioid addiction or 
opioid addictions or opioid dependence or opioid dependences or opiate abuse or 
opiate abuses or opiate dependence or opiate addiction or opioid abuse or opioid 
abuses) ) OR SU ( (opioid related disorders or opioid-related disorders or opioid 
addiction or opioid addictions or opioid dependence or opioid dependences or opiate 
abuse or opiate abuses or opiate dependence or opiate addiction or opioid abuse or 
opioid abuses) ) 
3476 
11 
TI ( ((sexual* adj1 (trauma or abuse or violence or harassment or assault or assults 
or assulted) or (sex* adj1 offense or offenses) or rape or raped)) ) OR AB ( ((sexual* 
adj1 (trauma or abuse or violence or harassment or assault or assults or assulted) or 
(sex* adj1 offense or offenses) or rape or raped)) ) OR SU ( ((sexual* adj1 (trauma or 
abuse or violence or harassment or assault or assults or assulted) or (sex* adj1 
offense or offenses) or rape or raped)) ) 
6905 
12 S7 or S8 or S9 or S10 or S11 228968 
13 S6 and S12 283 
14 limit 13 to english language 282 
15 limit 14 to yr=”2012-Current” 191 
CCRCT [EBM Reviews - Cochrane Central Register of Controlled Trials July 2020] 
# Search Statement Results 
1 exp Transcranial Magnetic Stimulation/ or Magnetic Stimulation Therapy/ 1537 
2 
(TMS or ((transcrani* or crani* or brain*) adj4 (electrostim* or electro-stim* or 
electrotherap* or electro-therap*)) or electrical stimulation or electrical treatment or 
((brain* or cortex or cortical or transcranial* or cranial or magneti*) adj4 stimulat*) or 
(transcranial magnetic stimulation or rTMS or cranial electrostimulation or cranial 
electrotherapy)).ti,ab,kw. 
17132 
3 (MeRT or magnetic eResonance therapy or magnetic e-Resonance therapy).ti,ab,kw. 8 
4 
(magnetic EEG?EKG guidance resonance therapy or magnetic EEG guided 
resonance therapy or magnetic EEG-guided resonance therapy or magnetic EKG-
guided resonance therapy or magnetic EKG-guided resonance therapy).ti,ab,kw. 
0 
5 
(EEG?EKG guided TMS or EEG guided TMS or EEG-guided TMS or EKG guided 
TMS or EKG-guided TMS or EEG guided transcranial magnetic stimulation or EEG-
guided transcranial magnetic stimulation or EKG guided transcranial magnetic 
stimulation or EKG guided transcranial magnetic stimulation or q-EEG or quantitative 
EEG).ti,ab,kw. 
309 
6 or/1-5 17606 
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7 Stress Disorders, Post-Traumatic/ or exp Brain Injuries, Traumatic/ or exp Opioid-Related Disorders/ or Sexual Harassment/ or exp Sex Offenses/  6821 
8 (PTSD or post-traumatic stress disorder or posttraumatic stress disorder or post-
traumatic stress disorders or posttraumatic stress disorders or post-traumatic 
neuroses or posttraumatic neuroses or moral injury or moral injuries).ti,ab,kw. 
5644 
9 (TBI or TBIs or traumatic brain injury or traumatic brain injuries or brain trauma or 
brain traumas or traumatic encephalopathy or traumatic encephalopathies).ti,ab,kw. 4539 
10 (opioid related disorders or opioid-related disorders or opioid addiction or opioid 
addictions or opioid dependence or opioid dependences or opiate abuse or opiate 
abuses or opiate dependence or opiate addiction or opioid abuse or opioid 
abuses).ti,ab,kw. 
2061 
11 (sexual* trauma or sexual* abuse or sexual* violence or sex* offense or sex* 
offenses or sexual* harassment or sexual* assault or sexual* assaults or sexual* 
assaulted or rape or raped).ti,ab,kw. 
1531 
12 or/7-11 15898 
13 6 and 12 418 
14 limit 13 to english language 230 
15 limit 14 to yr=”2012-Current” 202 
PsycINFO [Ovid, APA PsycInfo 1806 to August Wk 1 2020] 
# Search Statement Results 
1 exp Transcranial Magnetic Stimulation/ 8425 
2 
(TMS or ((transcrani* or crani* or brain*) adj4 (electrostim* or electro-stim* or 
electrotherap* or electro-therap*)) or electrical stimulation or electrical treatment or 
((brain* or cortex or cortical or transcranial* or cranial or magneti*) adj4 stimulat*) or 
(transcranial magnetic stimulation or rTMS or cranial electrostimulation or cranial 
electrotherapy)).ti,ab,id. 
31753 
3 (MeRT or magnetic eResonance therapy or magnetic e-Resonance therapy).ti,ab,id. 25 
4 
(magnetic EEG?EKG guidance resonance therapy or magnetic EEG guided 
resonance therapy or magnetic EEG-guided resonance therapy or magnetic EKG-
guided resonance therapy or magnetic EKG-guided resonance therapy).ti,ab,id. 
0 
5 
(EEG?EKG guided TMS or EEG guided TMS or EEG-guided TMS or EKG guided 
TMS or EKG-guided TMS or EEG guided transcranial magnetic stimulation or EEG-
guided transcranial magnetic stimulation or EKG guided transcranial magnetic 
stimulation or EKG guided transcranial magnetic stimulation or q-EEG or quantitative 
EEG).ti,ab,id. 
848 
6 or/1-5 32760 
7 exp Posttraumatic Stress Disorder/ or exp Traumatic Brain Injury/ or exp “Opioid Use Disorder”/ or exp Sexual Harassment/ or exp Sex Offenses/  92255 
8 (PTSD or post-traumatic stress disorder or posttraumatic stress disorder or post-
traumatic stress disorders or posttraumatic stress disorders or post-traumatic 
neuroses or posttraumatic neuroses or moral injury or moral injuries).ti,ab,id. 
42280 
9 (TBI or TBIs or traumatic brain injury or traumatic brain injuries or brain trauma or 
brain traumas or traumatic encephalopathy or traumatic encephalopathies).ti,ab,id. 18909 
10 (opioid related disorders or opioid-related disorders or opioid addiction or opioid 
addictions or opioid dependence or opioid dependences or opiate abuse or opiate 
abuses or opiate dependence or opiate addiction or opioid abuse or opioid 
abuses).ti,ab,id. 
4358 
11 (sexual* trauma or sexual* abuse or sexual* violence or sex* offense or sex* 
offenses or sexual* harassment or sexual* assault or sexual* assaults or sexual* 
assaulted or rape or raped).ti,ab,id. 
42333 
12 or/7-12 122224 
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13 6 and 12 488 
14 limit 13 to english language 468 
15 limit 14 to yr=”2012-Current” 314 
 
5. Search for primary literature - TMS-all + Chronic pain-post2017 
Date searched: 08-10-20 
MEDLINE [Ovid MEDLINE(R) ALL 1946 to August 06, 2020] 
# Search Statement Results 
1 exp Transcranial Magnetic Stimulation/ or Magnetic Stimulation Therapy/ 12590 
2 
(TMS or ((transcrani* or crani* or brain*) adj4 (electrostim* or electro-stim* or 
electrotherap* or electro-therap*)) or electrical stimulation or electrical treatment or 
((brain* or cortex or cortical or transcranial* or cranial or magneti*) adj4 stimulat*) 




3 (MeRT or magnetic eResonance therapy or magnetic e-Resonance therapy).ti,ab,kw. 
268 
4 
(magnetic EEG?EKG guidance resonance therapy or magnetic EEG guided 
resonance therapy or magnetic EEG-guided resonance therapy or magnetic EKG-
guided resonance therapy or magnetic EKG-guided resonance therapy).ti,ab,kw. 
0 
5 
(EEG?EKG guided TMS or EEG guided TMS or EEG-guided TMS or EKG guided 
TMS or EKG-guided TMS or EEG guided transcranial magnetic stimulation or 
EEG-guided transcranial magnetic stimulation or EKG guided transcranial 
magnetic stimulation or EKG guided transcranial magnetic stimulation or q-EEG or 
quantitative EEG).ti,ab,kw. 
1402 
6 or/1-5 99318 
7 Chronic Pain/ 14595 
8 ((chronic* or back or musculoskel* or intractabl* or neuropath* or phantom limb or 
fantom limb or neck or myofasc* or "temporomandib* joint*" or "temperomandib* 
joint*" or "tempromandib* joint*" or central or post*stroke or complex or regional or 
spinal cord) adj4 pain*) or (sciatica or back-ache or back*ache or lumbago or 
fibromyalg* or (trigemin* adj2 neuralg*) or (herp* adj2 neuralg*) or (diabet* adj2 
neuropath*) or (reflex adj4 dystroph*) or (sudeck* adj2 atroph*) or causalg* or 
whip-lash or whip*lash or polymyalg* or (failed back adj4 surg*) or (failed back 
adj4 syndrome*)).ti,ab,kw. 
207706 
9 7 or 8 207706 
10 6 and 9 2887 
11 limit 10 to english language 2719 
12 limit 11 to yr=”2017-current” 674 
CINAHL [EBSCO] 
# Search Statement Results 
1 (MH "Transcranial Magnetic Stimulation")   1215 
2 
TI ( (TMS or ((transcrani* or crani* or brain*) adj4 (electrostim* or electro-stim* or 
electrotherap* or electro-therap*)) or electrical stimulation or electrical treatment or 
((brain* or cortex or cortical or transcranial* or cranial or magneti*) adj4 stimulat*) 
or (transcranial magnetic stimulation or rTMS or cranial electrostimulation or 
cranial 
electrotherapy)) ) OR AB ((TMS or ((transcrani* or crani* or brain*) adj4 
(electrostim* or electro-stim* or electrotherap* or electro-therap*)) or electrical 
stimulation or electrical treatment or ((brain* or cortex or cortical or transcranial* or 
cranial or magneti*) adj4 stimulat*) or (transcranial magnetic stimulation or rTMS 
10359 
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or cranial electrostimulation or cranial electrotherapy)) ) OR SU ((TMS or 
((transcrani* or crani* or brain*) adj4 (electrostim* or electro-stim* or electrotherap* 
or electro-therap*)) or electrical stimulation or electrical treatment or ((brain* or 
cortex or cortical or transcranial* or cranial or magneti*) adj4 stimulat*) or 
(transcranial magnetic stimulation or rTMS or cranial electrostimulation or cranial 
electrotherapy)) ) 
3 
TI ( (MeRT or magnetic eResonance therapy or magnetic e-Resonance therapy) ) 
OR AB ( (MeRT or magnetic eResonance therapy or magnetic e-Resonance 
therapy) ) OR SU ( (MeRT or magnetic eResonance therapy or magnetic e-
Resonance therapy) ) 
40 
4 
TI ( (magnetic EEG?EKG guidance resonance therapy or magnetic EEG guided 
resonance therapy or magnetic EEG-guided resonance therapy or magnetic EKG-
guided resonance therapy or magnetic EKG-guided resonance therapy) ) OR AB ( 
(magnetic EEG?EKG guidance resonance therapy or magnetic EEG guided 
resonance therapy or magnetic EEG-guided resonance therapy or magnetic EKG-
guided resonance therapy or magnetic EKG-guided resonance therapy) ) OR SU ( 
(magnetic EEG?EKG guidance resonance therapy or magnetic EEG guided 
resonance therapy or magnetic EEG-guided resonance therapy or magnetic EKG-
guided resonance therapy or magnetic EKG-guided resonance therapy) ) 
0 
5 
TI ( (EEG?EKG guided TMS or EEG guided TMS or EEG-guided TMS or EKG 
guided TMS or EKG-guided TMS or EEG guided transcranial magnetic stimulation 
or EEG-guided transcranial magnetic stimulation or EKG guided transcranial 
magnetic stimulation or EKG guided transcranial magnetic stimulation or q-EEG or 
quantitative EEG) ) OR AB ( (EEG?EKG guided TMS or EEG guided TMS or EEG-
guided TMS or EKG guided TMS or EKG-guided TMS or EEG guided transcranial 
magnetic stimulation or EEG-guided transcranial magnetic stimulation or EKG 
guided transcranial magnetic stimulation or EKG guided transcranial magnetic 
stimulation or q-EEG or quantitative EEG) ) OR SU ( (EEG?EKG guided TMS or 
EEG guided TMS or EEG-guided TMS or EKG guided TMS or EKG-guided TMS 
or EEG guided transcranial magnetic stimulation or EEG-guided transcranial 
magnetic stimulation or EKG guided transcranial magnetic stimulation or EKG 
guided transcranial magnetic stimulation or q-EEG or quantitative EEG) ) 
226 
6 S1 OR S2 OR S3 OR S4 OR S5 10622 
7 (MH "Chronic Pain") 12958 
8 
TI ( ((chronic* or back or musculoskel* or intractabl* or neuropath* or phantom 
limb or fantom limb or neck or myofasc* or "temporomandib* joint*" or 
"temperomandib* joint*" or "tempromandib* joint*" or central or post*stroke or 
complex or regional or spinal cord) adj4 pain*) or (sciatica or back-ache or 
back*ache or lumbago or fibromyalg* or (trigemin* adj2 neuralg*) or (herp* adj2 
neuralg*) or (diabet* adj2 neuropath*) or (reflex adj4 dystroph*) or (sudeck* adj2 
atroph*) or causalg* or whip-lash or whip*lash or polymyalg* or (failed back adj4 
surg*) or (failed back adj4 syndrome*)) ) OR AB ( ((chronic* or back or 
musculoskel* or intractabl* or neuropath* or phantom limb or fantom limb or neck 
or myofasc* or "temporomandib* joint*" or "temperomandib* joint*" or 
"tempromandib* joint*" or central or post*stroke or complex or regional or spinal 
cord) adj4 pain*) or (sciatica or back-ache or back*ache or lumbago or fibromyalg* 
or (trigemin* adj2 neuralg*) or (herp* adj2 neuralg*) or (diabet* adj2 neuropath*) or 
(reflex adj4 dystroph*) or (sudeck* adj2 atroph*) or causalg* or whip-lash or 
whip*lash or polymyalg* or (failed back adj4 surg*) or (failed back adj4 
syndrome*)) ) OR SU ( ((chronic* or back or musculoskel* or intractabl* or 
neuropath* or phantom limb or fantom limb or neck or myofasc* or 
"temporomandib* joint*" or "temperomandib* joint*" or "tempromandib* joint*" or 
central or post*stroke or complex or regional or spinal cord) adj4 pain*) or (sciatica 
or back-ache or back*ache or lumbago or fibromyalg* or (trigemin* adj2 neuralg*) 
or (herp* adj2 neuralg*) or (diabet* adj2 neuropath*) or (reflex adj4 dystroph*) or 
5599 
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(sudeck* adj2 atroph*) or causalg* or whip-lash or whip*lash or polymyalg* or 
(failed back adj4 surg*) or (failed back adj4 syndrome*)) ) 
9 S7 or S8 18008 
10 S6 and S9 136 
11 limit 10 to english language 136 
12 limit 11 to yr=”2017-current” 52 
CCRCT [EBM Reviews - Cochrane Central Register of Controlled Trials July 2020] 
# Search Statement Results 
1 exp Transcranial Magnetic Stimulation/ or Magnetic Stimulation Therapy/ 1537 
2 
(TMS or ((transcrani* or crani* or brain*) adj4 (electrostim* or electro-stim* or 
electrotherap* or electro-therap*)) or electrical stimulation or electrical treatment or 
((brain* or cortex or cortical or transcranial* or cranial or magneti*) adj4 stimulat*) 




3 (MeRT or magnetic eResonance therapy or magnetic e-Resonance therapy).ti,ab,kw. 8 
4 
(magnetic EEG/EKG guidance resonance therapy or magnetic EEG guided 
resonance therapy or magnetic EEG-guided resonance therapy or magnetic EKG-
guided resonance therapy or magnetic EKG-guided resonance therapy).ti,ab,kw. 
0 
5 
(EEG?EKG guided TMS or EEG guided TMS or EEG-guided TMS or EKG guided 
TMS or EKG-guided TMS or EEG guided transcranial magnetic stimulation or 
EEG-guided transcranial magnetic stimulation or EKG guided transcranial 
magnetic stimulation or EKG guided transcranial magnetic stimulation or q-EEG or 
quantitative EEG).ti,ab,kw. 
309 
6 or/1-5 17606 
7 Chronic Pain/ 2274 
8 ((chronic* or back or musculoskel* or intractabl* or neuropath* or phantom limb or 
fantom limb or neck or myofasc* or "temporomandib* joint*" or "temperomandib* 
joint*" or "tempromandib* joint*" or central or post*stroke or complex or regional or 
spinal cord) adj4 pain*) or (sciatica or back-ache or back*ache or lumbago or 
fibromyalg* or (trigemin* adj2 neuralg*) or (herp* adj2 neuralg*) or (diabet* adj2 
neuropath*) or (reflex adj4 dystroph*) or (sudeck* adj2 atroph*) or causalg* or 
whip-lash or whip*lash or polymyalg* or (failed back adj4 surg*) or (failed back 
adj4 syndrome*)).ti,ab,kw. 
45397 
9 7 or 8 45397 
10 6 and 9 1342 
11 limit 10 to english language 806 
12 limit 11 to yr=”2017-current” 307 
PsycINFO [Ovid, APA PsycInfo 1806 to August Wk 1 2020] 
# Search Statement Results 
1 exp Transcranial Magnetic Stimulation/  8425 
2 
(TMS or ((transcrani* or crani* or brain*) adj4 (electrostim* or electro-stim* or 
electrotherap* or electro-therap*)) or electrical stimulation or electrical treatment or 
((brain* or cortex or cortical or transcranial* or cranial or magneti*) adj4 stimulat*) 




3 (MeRT or magnetic eResonance therapy or magnetic e-Resonance therapy).ti,ab,kw. 25 
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4 
(magnetic EEG/EKG guidance resonance therapy or magnetic EEG guided 
resonance therapy or magnetic EEG-guided resonance therapy or magnetic EKG-
guided resonance therapy or magnetic EKG-guided resonance therapy).ti,ab,id. 
0 
5 
(EEG?EKG guided TMS or EEG guided TMS or EEG-guided TMS or EKG guided 
TMS or EKG-guided TMS or EEG guided transcranial magnetic stimulation or 
EEG-guided transcranial magnetic stimulation or EKG guided transcranial 
magnetic stimulation or EKG guided transcranial magnetic stimulation or q-EEG or 
quantitative EEG).ti,ab,id. 
848 
6 or/1-5 32760 
7 exp Chronic Pain/ 13491 
8 (((chronic* or back or musculoskel* or intractabl* or neuropath* or phantom limb or 
fantom limb or neck or myofasc* or "temporomandib* joint*" or "temperomandib* 
joint*" or "tempromandib* joint*" or central or post*stroke or complex or regional or 
spinal cord) adj4 pain*) or (sciatica or back-ache or back*ache or lumbago or 
fibromyalg* or (trigemin* adj2 neuralg*) or (herp* adj2 neuralg*) or (diabet* adj2 
neuropath*) or (reflex adj4 dystroph*) or (sudeck* adj2 atroph*) or causalg* or 
whip-lash or whip*lash or polymyalg* or (failed back adj4 surg*) or (failed back 
adj4 syndrome*))).ti,ab,id. 
35688 
9 7 or 8 36491 
10 6 and 9 861 
11 limit 10 to english language 821 




Date Searched: 08-27-20 
# Search Statement Results 
1 
Condition or disease: PTSD or post-traumatic stress disorder or posttraumatic 
stress disorder or traumatic brain injury or TBI or opioid or opioids or sexual 
trauma or sexual abuse or sexual violence or chronic pain 
Other terms: TMS or transcranial magnetic stimulation or MeRT or magnetic 
eResonance therapy or magnetic EEG/EKG guidance resonance therapy EEG 
guidance or EKG guidance or magnetic stimulation therapy 
0 
2 
Condition or disease: PTSD or post-traumatic stress disorder or posttraumatic 
stress disorder 
Other terms: TMS or transcranial magnetic stimulation 
26 
3 
Condition or disease: PTSD or post-traumatic stress disorder or posttraumatic 
stress disorder 
Other terms: MeRT 
2 
4 Condition or disease: traumatic brain injury or TBI or concussion Other terms: TMS or transcranial magnetic stimulation 3 
5 Condition or disease: traumatic brain injury or TBI or concussion Other terms: MeRT 1 
6 Condition or disease: opioid or opioids Other terms: TMS or transcranial magnetic stimulation 12 
8 Condition or disease: chronic pain 
Other terms: TMS or transcranial magnetic stimulation 42 
*No results for: sexual trauma and any intervention; EEG/EKG-guided resonance therapy and any condition; MeRT 
and opioid addiction, chronic pain 
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APPENDIX C: EXCLUDED STUDIES 
Exclude reasons: 1=Ineligible population, 2=Ineligible intervention, 3=Ineligible comparator, 
4=Ineligible outcome, 5=Ineligible timing, 6=Ineligible study design, 7=Ineligible publication 
type 8=Outdated or ineligible systematic review, 9=Non-prioritized pain area, 10=Unable to 
locate full-text 
# Citation Exclude Reason 
1 
Aamir, A., et al. (2020). "Repetitive Magnetic Stimulation for the Management of 




Adamson, M., et al. (2020). "Repetitive transcranial magnetic stimulation for 
improving cognition in veterans with TBI: results from pilot clinical trial." Brain 
Stimulation 12(2): 551-. 
E4 
3 
Adamson, M., et al. (2020). "Repetitive transcranial magnetic stimulation for 
improving cognition in veterans with TBI: results from pilot clinical trial." Brain 
Stimulation 12(2): 551-. 
E6 
4 Ansado, J., et al. (2019). "Impact of non-invasive brain stimulation on transcallosal 
modulation in mild traumatic brain injury: a multimodal pilot investigation." Brain 
Injury 33(8): 1021-1031. 
E4 
5 Akyuz, G. and E. Giray (2019). "Noninvasive neuromodulation techniques for the 
management of phantom limb pain: a systematic review of randomized controlled 
trials." International Journal of Rehabilitation Research 42(1): 1-10. 
 
E7 
6 Baptista, A. F., et al. (2019). "Latin American and Caribbean consensus on 
noninvasive central nervous system neuromodulation for chronic pain 
management (LAC<sub>2</sub>-NIN-CP)." The Pain Report 4(1): e692. 
E7 
7 Berlim, M. T. and F. Van Den Eynde (2014). "Repetitive transcranial magnetic 
stimulation over the dorsolateral prefrontal cortex for treating posttraumatic stress 
disorder: an exploratory meta-analysis of randomized, double-blind and sham-
controlled trials." Canadian Journal of Psychiatry - Revue Canadienne de 
Psychiatrie 59(9): 487-496. 
E7 
8 Berlim, M. T. and F. Van Den Eynde (2014). "Repetitive transcranial magnetic 
stimulation over the dorsolateral prefrontal cortex for treating posttraumatic stress 
disorder: an exploratory meta-analysis of randomized, double-blind and sham-
controlled trials." Canadian Journal of Psychiatry - Revue Canadienne de 
Psychiatrie 59(9): 487-496. 
E7 
9 Bhatia, R., et al. (2017). "Transcranial magnetic stimulation of dorsolateral 
prefrontal cortex in chronic pain management." Brain Stimulation 10(2): 434-435. 
E6 
10 Blanchard, D. and S. Bourgeois (2017). "Efficacy of non-invasive brain stimulation 
for people experiencing chronic pain." International Journal of Evidence-Based 
Healthcare 15(2): 79-80. 
E6 
11 Bogdanova, Y., et al. (2015). "Sleep problems, treatment and recovery in veterans 
with blast exposure, TBI and PTSD." Archives of physical medicine and 
rehabilitation 96(10): e3-e4. 
E6 
12 Bursali, C., et al. (2019). "Effectiveness of repetitive transcranial magnetic 
stimulation in patients with failed back surgery syndrome." Annals of the rheumatic 
diseases 78. 
E6 
13 Castel-Lacanal, E., et al. (2014). "Transcranial magnetic stimulation in brain 
injury." Annales Francaises d Anesthesie et de Reanimation 33(2): 83-87. 
E7 
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14 Cervigni, M., et al. (2018). "Repetitive transcranial magnetic stimulation for chronic 
neuropathic pain in patients with bladder pain syndrome/interstitial cystitis." 
Neurourology & Urodynamics 37(8): 2678-2687. 
E9 
15 Chan, P., et al. (2019). "The Role of Fast or Slow Repetitive Transcranial Magnetic 
Stimulation in Civilian Post-Traumatic Stress Disorder: a Randomized, Sham-
Controlled Trial." Brain Stimulation 12(4): e132-. 
E6 
16 Choi, G. S., et al. (2018). "Effect of high-frequency repetitive transcranial magnetic 
stimulation on chronic central pain after mild traumatic brain injury: A pilot study." 
Journal of Rehabilitation Medicine 50(3): 246-252 
E9 
17 Cirillo, P., et al. (2019). "Transcranial magnetic stimulation in anxiety and trauma-
related disorders: A systematic review and meta-analysis." Brain and Behavior 
9(6): e01284. 
E7 
18 Cogne, M., et al. (2017). "Seizure induced by repetitive transcranial magnetic 
stimulation for central pain: Adapted guidelines for post-stroke patients." Brain 
Stimulation 10(4): 862-864. 
E6 
19 Cohen, B., et al. (2017). "Deep tms augmentation treatment for fibromyalgia: a 
safety and feasibility study." Brain stimulation. Conference: 2nd international brain 
stimulation conference. Spain 10(2): 450. 
E6 
20 Coles, A., et al. (2018). "A review of brain stimulation methods to treat substance 
use disorders." American Journal on Addictions 27(2): 71-91 
E2 
21 Cordero-Gessa, A. and L. Espejo-Antúnez (2019). "Eficacia de la estimulación 
magnética transcraneal de baja intensidad en mujeres diagnosticadas de 
fibromialgia. Un estudio piloto." Fisioterapia 41(2): 99-106. 
E8 
22 Etoh, S. (2017). "Effect of the repetitive transcranial magnetic stimulation and 
motor imagery therapy on the central pain after stroke." 
E10 
23 Dhaliwal, S. K., et al. (2015). "Non-Invasive Brain Stimulation for the Treatment of 
Symptoms Following Traumatic Brain Injury." Frontiers in psychiatry Frontiers 
Research Foundation 6: 119. 
 
24 Ferreira, N. R., et al. (2019). "The efficacy of transcranial direct current stimulation 
and transcranial magnetic stimulation for chronic orofacial pain: A systematic 
review." PLoS ONE [Electronic Resource] 14(8): e0221110. 
E7 
25 Ferrulli, A., et al. (2019). "Deep transcranial magnetic stimulation in patients with 
obesity: italian safety data." Obesity facts 12(11). 
E6 
26 Freire, R. C., et al. (2020). "Neurostimulation in Anxiety Disorders, Post-traumatic 
Stress Disorder, and Obsessive-Compulsive Disorder." Advances in Experimental 
Medicine & Biology 1191: 331-346. 
E6 
27 Fryml, L. D., et al. (2018). "The role of rTMS for patients with severe PTSD and 
depression." Evidence-Based Mental Health 21(1): 39-40. 
E5 
28 Gao, F., et al. (2017). "Repetitive transcranial magnetic stimulation for pain after 
spinal cord injury: a systematic review and meta-analysis." Journal of 
Neurosurgical Sciences 61(5): 514-522. 
E7 
29 Geraets, C. N. W., et al. (2019). "Lack of analgesic effects of transcranial pulsed 
electromagnetic field stimulation in neuropathic pain patients: A randomized 
double-blind crossover trial." Neuroscience Letters 699: 212-216. 
E2 
30 Geraets, C. N. W., et al. (2019). "Lack of analgesic effects of transcranial pulsed 
electromagnetic field stimulation in neuropathic pain patients: A randomized 
double-blind crossover trial." Neuroscience Letters 699: 212-216. 
E1 
31 Gertler, P., et al. (2015). "Non-pharmacological interventions for depression in 
adults and children with traumatic brain injury." Cochrane Database of Systematic 
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APPENDIX D: STUDIES INCLUDED IN EXISTING SYSTEMATIC REVIEW (O’CONNELL 2018) 
Author, 
Year 





Country of study: Egypt 
Setting: Dept of Neurology, hospital-based 
Condition: chronic phantom limb pain 
Prior management details: unresponsive to 
various pain medications n = 27, 17 active 
and 10 sham 
Age, mean (SD): active group 52.01 (12.7) 
years, sham group 53.3 (13.3) years 
Duration of symptoms, mean (SD) months: 
active group 33.4 (39.3), sham group 31.9 
(21.9) 
Gender distribution: active group 13 M, 4 F; 
sham group 6 M, 4 F 
Stimulation type: rTMS 
Stimulation parameters: frequency 20 Hz; 
coil orientation not specified, number of 
trains 10; duration 
of trains 10 s; ITI 50 s; total number of 
pulses 2000 
Stimulation location: M1 stump region 
Number of treatments: x 5, daily 
Control type: sham - coil angled away 
from scalp 
Primary: pain VAS (anchors not 
reported), LANNS 
When taken: poststimulation session 1 
and 5 and at 1 month and 2 months 
post-treatment 







Country of study: France 
Setting: laboratory 
Condition: neuropathic pain (mixed central, 
peripheral and facial) 
Prior management details: refractory to 
drug management, candidates for invasive 
MCS n=14                        Age: 31-66 years; 
mean 53 (SD 11) 
Duration of symptoms: mean 6.9 years (SD 
4) 
Gender distribution: 10 M, 4 F 
Stimulation type: rTMS figure-of-8 coil 
Stimulation parameters: 
Condition 1: frequency 20 Hz; coil 
orientation posteroanterior; 90% RMT; 
number of trains 20; duration 
of trains 4 s; ITI 84 s; total number of 
pulses 1600 
Condition 2: frequency 1 Hz; coil 
orientation lateromedial; number of trains 
1; duration of trains 26 min, 
total number of pulses 1600 
Condition 3: sham - same as for condition 
2 with coil angled away perpendicular to 
scalp 
Stimulation location: M1 contralateral to 
painful side 
Number of treatments: 1 for each 
condition 
Primary: VAS 0-10 cm, anchors "no 
pain" to "unbearable pain" 
When taken: immediately 








Country of study: France 
Setting: laboratory-based 
Condition: neuropathic pain (mixed central, 
peripheral and facial) 
Prior management details: refractory to 
Stimulation type: rTMS, figure-of-8 coil 
Stimulation parameters: 
Condition 1: frequency 20 Hz; coil 
orientation posteroanterior; 90% RMT; 
number of trains 20; duration 
Primary: 0-10 NRS (anchors "no pain" 
to "unbearable pain") 
When taken: daily for 2 wks 
poststimulation 
Secondary: none 
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drug management, candidates for invasive 
MCS 
n = 30 
Age: 31-72 years, mean 55 (SD 10.5) 
Duration of symptoms: mean 5 years (SD 
3.9) 
Gender distribution: 23 M, 7 F 
of trains 4 s; ITI 84 s; total number of 
pulses 1600 
Condition 2: frequency 20 Hz, coil 
orientation lateromedial; number of trains 
20; duration of trains 4 s; 
ITI 84 s; total number of pulses 1600 
Condition 3: sham - same as for active 
conditions with coil angled away 
perpendicular to scalp 
Stimulation location: M1 contralateral to 
painful side 








Country of study: France 
Setting: laboratory-based 
Condition: chronic neuropathic pain (mixed) 
Prior management details: resistant to 
conventional pharmacological treatment 
n = 45 
Age: 31-72 years (mean 55) 
Duration of symptoms: "chronic" 
Gender distribution: 28 M, 17 F 
Stimulation type: rTMS 
Stimulation parameters: frequency 20 Hz; 
coil orientation not specified, number of 
trains 20; duration 
of trains 4 s; ITI 84 s; total number of 
pulses 1600 
Stimulation location: M1 hand area                 
Number of treatments: 1 per group 
Control type: sham coil - same sound and 
appearance, no control for sensory cues                                                                                                                                                                                                                
Primary: pain NRS anchors 0 = no 
pain, 10 = unbearable pain 
When taken: daily for 2 wks following 
each stimulation 
Secondary: none relevant 
Avery 20135 Parallel RCT Country of study: USA 
Setting: unclear 
Condition: chronic widespread pain 
Prior management details: not reported 
n = 19 
Age mean (SD): active 54.86 (7.65) years, 
sham 52.09 (10.02) years 
Duration of symptoms (months mean (SD)): 
active group 11 (4.26), sham group 15.64 
(6.93) 
Gender distribution: all F 
Stimulation type: rTMS                                                                                                                                     
Stimulation parameters: frequency 10 Hz; 
coil orientation not specified; 120% RMT; 
number of trains 
75; duration of trains 4 s; ITI 26 s; total 
number of pulses 3000 
Stimulation location: L DLPFC 
Number of treatments: 15 sessions over 
4 wks 
Control type: sham coil - controls for 
visual, auditory and scalp sensory cues 
Primary: pain NRS 0-10 anchors not 
reported 
When taken: end of treatment period, 1 
month following and 3 months 
following 
Secondary: pain interference BPI 
QoL SF-36 
AEs: multiple minor; no clear difference 







Country of study: USA 
Setting: laboratory 
Condition: peripheral neuropathic pain 
Prior management details: not specified 
n = 4 
Age: 33-58 years; mean 46 (SD 11) 
Stimulation type: rTMS, figure-of-8 coil 
Stimulation parameters: frequency 10 Hz; 
coil orientation not specified; 100% RMT; 
number of trains 
40; duration of trains 10 s; ITI 20 s; total 
number of pulses 4000 
Primary: average daily pain 0-10 Likert 
scale, anchors "no pain at all" to "worst 
pain imaginable" 
When taken: post-stimulation for each 
condition (unclear how many days 
post) and daily for 3 wks 
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Duration of symptoms: 5-12 years; mean 
10.25 (SD 3.5) 
Gender distribution: 1 M, 3 F 
Stimulation location: L PFC 
Number of treatments: 3 over a 5-d 
period   Control type: neuronetics sham 
coil (looks and sounds identical)                
poststimulation 
Secondary: none 
Boyer 20147 Parallel RCT Country of study: France 
Setting: specialised pain treatment centre 
Condition: fibromyalgia 
Prior management details: stable treatment 
for more than 1 month before enrolment 
n = 38 
Age, mean (SD): active group 49.1(10.6) 
years, sham group 47.7 (10.4) years 
Duration of symptoms, mean (SD): active 
group 3.7 (4.5) years, sham group 3.6 (3.8) 
Gender distribution: 37 F, 1 M 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation anteroposterior; 90% 
RMT; number of trains 
20; duration of trains 10 s; ITI 50 s; total 
number of pulses 2000 
Stimulation location: L M1 
Number of treatments: 14 sessions. 10 
sessions in 2 wks followed by 
maintenance phase of 1 session 
at wks 4, 6, 8 and 10 
Control type: sham coil - did not control 
for sensory cues 
Primary: pain VAS 0 = no pain, 10 = 
maximal pain imaginable 





Parallel RCT Country of study: Spain 
Setting: outpatient clinic 
Condition: fibromyalgia (with major 
depression) 
Prior management details: unclear 
n = 26 
Age: active group 47.5 (SD 5.7) years, 
sham group 54.9 (SD 4.9) years 
Duration of symptoms: unclear "chronic" 
Gender distribution: 2 M, 24 F 
Stimulation type: rTMS 
Stimulation parameters: frequency 1 Hz; 
coil orientation not specified; 110% RMT; 
number of trains 20; 
duration of trains 60 s; ITI 45 s; number 
of pulses 1200 
Stimulation location: R DLPFC 
Number of treatments: up to 20 on 
consecutive working days 
Control type: coil angled 45º from the 
scalp 
Primary: Likert pain scale 0-10, 
anchors "no pain" to "extreme pain" 
When taken: 2 wks, 4 wks and 8 wks 




Parallel RCT Country of study: Brazil 
Setting: not specified 
Condition: chronic myofascial pain in the 
upper body 
Prior management details: not reported 
n = 24 
Age, mean (SD): active group 45.83 ( 9.63) 
years, sham group 44.83 (14.09) years 
Duration of symptoms: not reported 
Gender distribution: all F 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation 45º from midline, 80% 
RMT, number of trains 
16; duration of trains 10 s; ITI 26 s; total 
number of pulses 1600 
Stimulation location: L M1 
Number of treatments: 10 sessions, 
timescale not specified 
Control type: sham coil - same sound and 
appearance and sensation 
Primary: pain NRS anchors 0 = no 
pain, 10 = worst possible pain 
When taken: postintervention 
Secondary: AEs 




Parallel RCT Country of study: Brazil 
Setting: neurology dept 
Condition: CPSP 
Prior management details: stable 
medication for 30 d preceding baseline 
n = 23 
Age, mean (SD): active group 55 (9.67) 
years, sham group SD 57.8 (11.86) years 
Duration of symptoms, mean (SD): active 
group 64.18 (49.27) months, sham group 
50.1 (28.04)                
Gender distribution: active group 45% M, 
sham group 50% M 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation not specified, 120% RMT, 
number of trains 
25; duration of trains 5 s; ITI 25s; total 
number of pulses 1250 
Stimulation location: L premotor/DLPFC 
Number of treatments: 10 sessions daily 
for 2 wks 
Control type: sham coil - same sound and 
appearance, no control for sensory cues 
Primary: pain NRS anchors not 
reported 
When taken: end of intervention, 1, 2, 
and 4 wks postintervention 
Secondary: AEs, QoL (SF-36) 
Defrin 200711 Parallel RCT  Country of study: Israel 
Setting: outpatient department 
Condition: post-SCI central neuropathic 
pain 
Prior management details: refractory to 
drug, physical therapy and complementary 
therapy management 
n = 12 
Age: 44-60 years; mean 54 (SD 6) 
Duration of symptoms: > 12 months 
Gender distribution: 7 M, 4 F 
Stimulation type: rTMS, figure-of-8 coil 
Stimulation parameters: frequency 5 Hz; 
coil orientation not specified; 115% RMT; 
number of trains 
500; duration of trains 10 s; ITI 30 s; total 
number of pulses 500 reported, likely to 
have been 25,000 
judging by these parameters 
Stimulation location: M1 - midline 
Number of treatments: x 10, x 1 daily on 
consecutive days     
Control type: sham coil - visually the 
same and makes similar background 
noise 
Primary: 15 cm 0-10 VAS pain 
intensity, anchors "no pain sensation" 
to "most intense pain sensation" 
When taken: pre and post each 
stimulation session 
Secondary: McGill pain questionnaire 






Country of study: USA 
Setting: laboratory 
Condition: chronic pancreatitis pain 
Prior management details: not specified 
n = 5 
Age: 44 (SD 11) 
Duration of symptoms: not specified, 
"chronic" 
Gender distribution: not specified 
Stimulation type: rTMS, figure-of-8 coil 
Stimulation parameters: frequency 1 Hz 
or 20 Hz; coil orientation not specified; 
90% RMT; number of trains not specified; 
duration of trains not specified; ITI not 
specified; total number of pulses 1600 
Stimulation location: L and R SII                   
Number of treatments: 1 for each 
condition 
Control type: sham, "specially designed 
sham coil". No further details 
Primary: pain VAS, anchors not 
specified 
When taken: after each stimulation 
session 
Secondary: none 




Parallel RCT Country of study: USA 
Setting: laboratory 
Condition: chronic visceral pain (chronic 
pancreatitis) 
Prior management details: most on 
continuous opioid therapy, most had 
received surgery for their 
pain 
n = 17, 9 in active group, 8 in sham group 
Age mean (SD): active group 41.11 (11.27) 
years, sham group 46.71 (13.03) years 
Duration of symptoms: > 2 years 
Gender distribution: 14 F, 3 M 
Stimulation type: rTMS 
Stimulation parameters: frequency 1 Hz; 
coil orientation not specified, number of 
trains 1; duration of 
trains not specified; intensity 70% 
maximum stimulator output, total number 
of pulses 1600 
Stimulation location: SII 
Number of treatments: 10, x 1 daily 
(wkdays only) 
Control type: sham rTMS coil 
Primary: pain VAS; 0 = no pain, 10 = 
most intense pain imaginable 
When taken: daily pain logs for 3 wks 
pre-intervention, daily post-stimulation 
during intervention period 
and at 3-wk follow-up 






Country of study: Japan 
Setting: laboratory 
Condition: intractable deafferentation pain 
(mixed central, peripheral and facial) 
Prior management details: intractable 
n = 20 
Age: 28-72 years 
Duration of symptoms: 1.5-24.3 years, 
mean 6.4 (SD 6) 
Gender distribution: 13 M, 7 F 
Stimulation type: rTMS, figure-of-8 coil 
Stimulation parameters: frequency 5 Hz; 
coil orientation not specified; 90% RMT; 
number of trains 10; 
duration of trains 10 s; ITI 50 s; total 
number of pulses 500 
Stimulation location: condition 1: M1; 
condition 2: primary sensory cortex; 
condition 3: pre-motor area; 
condition 4: supplementary motor area; 
condition 5: sham 
Number of treatments: 1 for each 
condition 
Control type: coil angled 45º from scalp 
with synchronised electrical scalp 
stimulations to mask sensation 
Primary: pain intensity VAS, anchors 
not specified 
When taken: 0, 30, 60, 90, 180 min 





Country of study: Japan 
Setting: multicentre, laboratory-based 
Condition: mixed neuropathic pain 
Prior management details: pain persisted 
despite "adequate treatments" 
n = 70 of whom 64 analysed 
Age mean (SD): 60.7 (10.6) years            
Duration of symptoms: 58.2 (10.6) months 
Gender distribution: 40 M, 24 F 
Stimulation type: rTMS 
Stimulation parameters: frequency 5 Hz; 
coil orientation parasagittal, number of 
trains 10; duration of 
trains 10 s; ITI 50 s, intensity 90% RMT, 
total number of pulses per session 500 
Stimulation location: M1 corresponding to 
painful region 
Number of treatments: 10, x 1 daily 
(consecutive working days) 
Control type: sham coil 
Current daily pain 0-100 VAS (anchors 
not reported), SF McGill, AEs 







Country of study: Germany 
Setting: laboratory 
Condition: PLP and CNP 
Prior management details: unclear 
n = 27 
Age: (median) PLP 46.6 years, CNP 51.1 
years 
Duration of symptoms: mean PLP 15.2 (SD 
14.8), CNP 3.9 (SD 4.1) years. 
Gender distribution: 16 M, 11 F 
Stimulation type: rTMS, figure-of-8 coil 
Stimulation parameters: 
Condition 1: frequency 1 Hz; coil 
orientation not specified; 95% RMT; 
number of trains not specified; duration 
of trains not specified; ITI not specified; 
total number of pulses 500 
Condition 2: frequency 5 Hz; coil 
orientation not specified; 95% RMT; 
number of trains not specified; duration 
of trains not specified; ITI not specified; 
total number of pulses 500 
Condition 3: sham frequency 2 Hz; coil 
orientation not specified; number of trains 
not specified; duration 
of trains not specified; ITI not specified; 
total number of pulses 500 
Stimulation location: M1, contralateral to 
painful side 
Number of treatments: x 1 for each 
condition                                                  
Control type: sham coil; mimics sight and 
sound of active treatment 
Primary: 0-100 mm VAS pain intensity, 
anchors "no pain" and "most intense 
pain imaginable" 
When taken: pre- and post-stimulation 
Secondary: none 
Jette 201317  Cross-over 
RCT 
Country of study: Canada 
Setting: outpatient rehabilitation centre 
Condition: post-SCI neuropathic pain 
Prior management details: almost all 
participants in various medications 
n = 18 
Age: range 31-69 years, mean (SD) 50 (9) 
Duration of symptoms: not reported 
Gender distribution: 11 M, 5 F 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation 45º posterolateral, 90% 
RMT for hand, 110% 
RMTA for leg, number of trains 40; 
duration of trains 5 s; ITI 25 s; total 
number of pulses 2000 
Stimulation location: M1 hand or leg area 
with neuronavigation 
Number of treatments: single session per 
condition, 1 session of sham 
Control type: sham coil - same sound and 
appearance and sensation 
Primary: pain NRS anchors 0 = no 
pain, 10 = worst possible pain 
When taken: immediately 
poststimulation, 20 min poststimulation 
Secondary: AEs - though no formal 
assessment reported 
Kang 200918 Cross-over 
RCT 
Country of study: South Korea 
Setting: university hospital outpatient setting 
Condition: post-SCI central neuropathic 
pain 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation angled 45º 
posterolaterally; 80% RMT; number 
Primary: NRS average pain over last 
24 h, anchors "no pain sensation" to 
"most intense pain sensation 
imaginable" 
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Prior management details: resistant to drug, 
physical or complementary therapies 
n = 11 
Age: 33-75 years, mean 54.8 
Duration of symptoms: chronic 
Gender distribution: 6 M, 5 F 
of trains 20; duration of trains 5 s; ITI 55 
s; total number pulses 1000 
Stimulation location: R M1, hand area 
Number of treatments: 5, x 1 daily 
Control type: coil elevated and angled 
away from the scalp 
When taken: immediately after the 3rd 
and 5th treatments and 1, 3, 5, and 7 
wks after the end of the 
stimulation period 
Khedr 200519 Parallel RCT Country of study: Egypt 
Setting: university hospital neurology 
department 
Condition: neuropathic pain, mixed central 
(poststroke) and facial (trigeminal neuralgia) 
pain 
Prior management details: refractory to 
drug management 
n = 48 
Age: poststroke 52.3 (SD 10.3) years, 
trigeminal neuralgia 51.5 (SD 10.7) years 
Duration of symptoms: poststroke 39 
months (SD 31), trigeminal neuralgia 18 
months (SD 17) 
Gender distribution: 8 M, 16 F 
Stimulation type: rTMS 
Stimulation parameters: frequency 20 Hz; 
coil orientation not specified; 80% RMT; 
number of trains 10; 
duration of trains 10 s; ITI 50 s; total 
number of pulses 2000 
Stimulation location: M1 contralateral to 
the side of worst pain 
Number of treatments: 5, x 1 on 
consecutive days 
Control type: coil elevated and angled 
away from scalp 
Primary: pain VAS, anchors not 
specified 
When taken: post 1st, 4th, and 5th 
stimulation session and 15 days after 
the last session 
Secondary: none 
Lee 201220 Parallel RCT  Country of study: Korea 
Setting: outpatient clinic 
Condition: fibromyalgia 
Prior management details: none reported 
n = 22 
Age mean (SD): low-frequency group 45.6 
(9.6) years, high-frequency group 53 (4.2) 
years, sham group 
51.3 (6.2) years 
Duration of symptoms (months mean (SD)): 
low-frequency group: 47.2 (20.1), high-
frequency group 
57.1 (6.4), sham group 44.7 (10.3) 
Gender distribution: all F 
Stimulation type: rTMS 
Stimulation parameters: 
Low-frequency group: frequency 1 Hz; 
coil orientation not specified, number of 
trains 2; duration of 
trains 800 s; ITI 60 s; total number of 
pulses 1600 
High-frequency group: frequency 10 Hz; 
coil orientation not specified, number of 
trains 25; duration of 
trains 8 s; ITI 10 s; total number of pulses 
2000 
Stimulation location: right DLPFC (low-
frequency), L M1 (high-frequency) 
Number of treatments: 10, x 1 daily 
(wkdays only) for 2 wks 
Control type: sham - coil orientated away 
from scalp 
Primary: 0-100 mm pain VAS; 0 = 
none, 100 = an extreme amount of 
pain 
When taken: post-treatment and at 1 
month follow-up 
Secondary: FIQ 






Country of study: France 
Setting: laboratory 
Condition: intractable neuropathic pain 
(mixed central and facial) 
Prior management details: refractory to 
drug management 
n = 14 
Age: 34-80 years, mean 57.2 
Duration of symptoms: not specified 
"chronic" 
Gender distribution: 6 M, 8 F 
Stimulation type: rTMS, figure-of-8 coil 
Stimulation parameters: frequency 10 Hz; 
coil orientation not specified; 80% RMT; 
number of trains 20; 
duration of trains 5 s; ITI 55 s; total 
number of pulses 1000 
Stimulation location: M1, contralateral to 
painful side 
Number of treatments: x 1 for each 
condition 
Control type: sham coil used (inert) 
Primary: 0-10 VAS, anchors not 
specified 







Country of study: France 
Setting: laboratory 
Condition: neuropathic pain (mixed central 
and peripheral) 
Prior management details: refractory to 
drug management 
n = 18 
Age: 28-75 years, mean 54.7 
Duration of symptoms: not specified 
"chronic" 
Gender distribution: 11 M, 7 F 
Stimulation type: rTMS, figure-of-8 coil                                                       
Stimulation parameters: 
Condition 1: frequency 10 Hz; coil 
orientation posteroanterior; 80% RMT; 
number of trains 20; duration 
of trains 5 s; ITI 55 s; total number of 
pulses 1000 
Condition 2: frequency 0.5 Hz; coil 
orientation posteroanterior; number of 
trains 1; duration of trains 20 
min; total number of pulses 600 
Condition 3: sham - same as for condition 
1 with sham coil 
Stimulation location: M1 contralateral to 
painful side 
Number of treatments: x 1 for each 
condition 
Primary: 0-10 VAS pain, anchors not 
specified 






Country of study: France 
Setting: laboratory 
Condition: neuropathic pain (mixed central, 
peripheral and facial) 
Prior management details: refractory to 
drug management 
n = 60 
Age: 27-79 years, mean 54.6 
Duration of symptoms: not specified 
"chronic" 
Gender distribution: 28 M, 32 F 
Stimulation type: rTMS, figure-of-8 coil 
Stimulation parameters: frequency 10 Hz; 
coil orientation posteroanterior; 80% 
RMT; number of trains 
20; duration of trains 5 s; ITI 55 s; total 
number of pulses 1000 
Stimulation location: M1 contralateral to 
painful side 
Number of treatments: x 1 for each 
condition 
Control type: sham coil 
Primary: 0-10 VAS pain, anchors not 
specified 
When taken: 5 min poststimulation 
Secondary: none 







Country of study: France 
Setting: laboratory 
Condition: unilateral chronic neuropathic 
pain (mixed central and peripheral) 
Prior management details: refractory to 
drug management 
n = 22 
Age: 28-75 years, mean 56.5 (SD 2.9) 
Duration of symptoms: 2-18 years, mean 
5.4 (SD 4.1) 
Gender distribution: 12 M, 10 F 
Stimulation type: rTMS, figure-of-8 coil 
Stimulation parameters: 
Condition 1: frequency 10 Hz; coil 
orientation posteroanterior; 90% RMT; 
number of trains 20; duration 
of trains 6 s; ITI 54 s; total number of 
pulses 1200 
Condition 2: frequency 1 Hz; coil 
orientation posteroanterior; 90% RMT; 
number of trains 1; duration of 
trains 20 min; total number of pulses 
1200 
Condition 3: sham coil 
Stimulation location: M1 contralateral to 
painful side 
Number of treatments: x 1 for each 
condition 
Primary: 0-10 VAS pain, anchors not 
specified 







Country of study: France 
Setting: laboratory 
Condition: neuropathic pain (mixed central, 
peripheral and facial) 
Prior management details: refractory to 
drug management for at least 1 year 
n = 46 
Age: 27-79 years, mean 54.2 
Duration of symptoms: chronic > 1 year 
Gender distribution: 23 M, 23 F 
Stimulation type: rTMS, figure-of-8 coil 
Stimulation parameters: 
Condition 1: frequency 10 Hz; coil 
orientation posteroanterior; 90% RMT; 
number of trains 20; duration 
of trains 6 s; ITI 54 s; total number of 
pulses 1200 
Condition 2: frequency 1 Hz; coil 
orientation posteroanterior; 90% RMT; 
number of trains 1; duration of 
trains 20 min; total number of pulses 
1200 
Condition 3: sham coil 
Stimulation location: M1 contralateral to 
painful side 
Number of treatments: x 1 for each 
condition 
Primary: 0-10 VAS, anchors not 
specified 




Parallel RCT Country of study: Colombia 
Setting: rehabilitation department 
Condition: phantom limb pain 
Prior management details: no difference 
across groups in use of NSAIDS, physical 
rehabilitation or psychological 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation 45° angle from midline, 
90% RMT number of 
trains 20; duration of trains 6 s; ITI 54 s; 
total number of pulses 1200 
Primary: pain NRS anchors 0 = no 
pain, 10 = worst pain possible 
When taken: 15 d and 30 d after 
treatment 
Secondary: AEs 
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therapy 
n = 54 
Age, mean (SD): active group 33.1 (6.6) 
years, sham group 8.2 (6.3) years 
Duration of symptoms: not reported 
Gender distribution: 50 M, 4 F 
Stimulation location: M1 contralateral to 
painful side, no neuronavigation Number 
of treatments: 10 sessions x 1 per work 
day for 2 wks 
Control type: sham coil - same sound and 
appearance, no control for sensory cues 
Medeiros 
201627 
Factorial RCT Country of study: Brazil 
Setting: not specified 
Condition: chronic myofascial pain 
syndrome 
Prior management details: not reported 
n = 46, of which 23 relevant to this review 
Age, mean (SD): active group 45.83 (9.63) 
years, sham group 46.73 (13.09) years 
Duration of symptoms: not reported 
Gender distribution: all F 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation 45° from midline, 80% 
RMT, number of trains 
not reported; duration of trains not 
reported; ITI s not reported; total number 
of pulses 1600 
Stimulation location: L M1 
Number of treatments: 10 days of 
stimulation 
Control type: sham coil - no details 
provided 
Primary: pain NRS anchors 0 = no 
pain, 10 = worst possible pain 
When taken: at end of intervention 
Secondary: none relevant 
Mhalla 
201128 
Parallel RCT Country of study: France Setting: laboratory 
Condition: fibromyalgia 
Prior management details: not reported but 
concomitant treatments allowed 
n = 40 
Age, mean (SD): active group 51.8 (11.6) 
years, sham group 49.6 (10) years 
Duration of symptoms (mean (SD) years): 
active group 13 (12.9), sham group 14.1 
(11.9) 
Gender distribution: all F 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation posteroanterior, number 
of trains 15; duration 
of trains 10 s; ITI 50 s, intensity 80% 
RMT, total number of pulses 1500 
Stimulation location: L M1 
Number of treatments: 14, x 1 daily for 5 
days, x 1 wkly for 3 wks, x 1 every two 
wks for 6 wks, x 
1 monthly for 3 months 
Control type: sham coil, did not control for 
sensory cues 
Primary: pain NRS; 0 = no pain, 10 = 
maximal pain imaginable 
When taken: day 5, 3 wks, 9 wks, 21 
wks, 25 wks 
Secondary: BPI interference scale, FIQ 
Nardone 
201729 
Parallel RCT Country of study: Italy and Austria 
Setting: laboratory 
Condition: below level post SCI, 
predominantly neuropathic pain 
Prior management details: > 4/10 pain 
despite rehabilitation and pharmacological 
treatment. All participants 
previously treated with antidepressant, 
anticonvulsants and analgesics for a 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation AP direction, 120% RMT, 
number of trains 25; 
duration of trains 5 s; ITI 25s; total 
number of pulses 1250 
Stimulation location: L PFC (no 
neuronavigation) 
Number of treatments: 10 sessions daily 
Primary: pain VAS anchors not 
reported When taken: postintervention, 
1 month postintervention 
Secondary: none relevant 
AEs 
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minimum period 
of 6 months 
n = 12 
Age, mean (range): active group 43.7 (26-
56) years, sham group 42.5 (24-62) years 
Duration of symptoms: not reported 
Gender distribution: 9 M, 3 F 
x 5 per wk for 2 wks 
Control type: sham coil - same sound and 





Country of study: UK 
Setting: laboratory 
Condition: mixed refractory neuropathic 
pain 
Prior management details: no benefit from 
medication or other stimulation approaches 
n = 40 (27 after loss to follow-up) 
Age, range: 27-79 years 
Duration of symptoms: not reported 
Gender distribution: 23 M, 17 F 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation AP direction, 90% RMT, 
number of trains 20; 
duration of trains 10 s; ITI 1 min; total 
number of pulses 2000 
Stimulation location: Site A: M1 hotspot, 
Site B M1 reorganised area, Site C 
(sham) occipital fissure 
Number of treatments: 3-5 sessions per 
wk for 5 sessions 
Control type: sham active stimulation of 
occipital fissure 
Primary: pain NRS anchors 0 = no pain 
10 = worst pain imagined 
When taken: postintervention, 3 wks 
postintervention 






Country of study: Italy 
Setting: laboratory 
n = 25 
Condition: neuropathic pain from diabetic 
neuropathy 
Prior management details: resistant to 
standard therapies for at least 1 year 
Age mean (SD): 70.6 (8.5) years 
Duration of symptoms (months mean (SD)): 
not reported 
Gender distribution: 9 F, 14 M 
Stimulation type: rTMS using H-coil 
Stimulation parameters: frequency 20 Hz; 
coil orientation H coil, number of trains 
30; duration of trains 
2.5 s; ITI 30 s, intensity 100% RMT, total 
number of pulses 1500 
Stimulation location: M1 lower limb (deep 
in central sulcus) 
Number of treatments: 5 per condition on 
consecutive days    
Control type: sham coil, controlled for 
scalp sensory, auditory and visual cues 
Primary: pain VAS 0-100, no pain to 
worst possible pain 
When taken: immediately 
poststimulation, 3 wks poststimulation 
Secondary: none relevant 




Parallel RCT Country of study: France 
Setting: laboratory 
Condition: fibromyalgia 
Prior management details: unclear 
n = 30 
Age: active group: 52.6 (SD 7.8) years, 
sham group 55.3 (SD 8.9) years 
Duration of symptoms: active group: 8.1 
(SD 7.9), sham group: 10.8 (SD 8.6) 
Gender distribution: 1 M, 29 F 
Stimulation type: rTMS, figure-of-8 coil 
Stimulation parameters: frequency 10 Hz; 
coil orientation posteroanterior; 80% 
RMT; number of trains 
25; duration of trains 8 s; ITI 52 s; total 
number of pulses 2000 
Stimulation location: M1 contralateral to 
painful side 
Number of treatments: 10, x 1 daily for 10 
working days 
Control type: sham rTMS coil. Mimics 
sight and sound of active treatment 
Primary: 0-10 NRS of average pain 
intensity over last 24 h, anchors "no 
pain" to "maximal pain imaginable" 
When taken: daily during treatment 
period and at 15, 30, and 60 days post-
treatment follow-up 
Secondary: FIQ 
When taken: as for primary outcome 
Picarelli 
201033 
Parallel RCT Country of study: Brazil 
Setting: laboratory 
Condition: CRPS type I 
Prior management details: refractory to best 
medical treatment 
n = 23 
Age mean (SD): active group 43.5 (12.1) 
years, sham group 40.6 (9.9) years 
Duration of symptoms (months mean (SD)): 
active group 82.33 (34.5), sham group 
79.27 (32.1) 
Gender distribution: 14 F, 9 M 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation posteroanterior, number 
of trains 25; duration 
of trains 10 s; ITI 60 s, intensity 100% 
RMT, total number of pulses 2500 
Stimulation location: M1 contralateral to 
painful limb 
Number of treatments: 10, x 1 daily on 
consecutive wkdays 
Control type: sham coil - did not control 
for sensory cues 
Primary: pain VAS; 0 = "no pain", 10 = 
"most severe pain"    
When taken: after first and last session 
then 1 and 3 months post-treatment 





Country of study: Germany 
Setting: laboratory 
Condition: CRPS type I 
Prior management details: drug 
management ceased for 48 h prior to study 
n = 10 
Age: 29-72 years, mean 51 
Duration of symptoms: 24-72 months, mean 
35 
Gender distribution: 3 M, 7 F 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation unspecified; 110% RMT; 
number of trains 10; duration of trains  
1.2 s; ITI 10 s; total number of pulses 120 
Stimulation location: M1 hand area 
Number of treatments: 1 for each 
condition 
Control type: coil angled 45º away from 
scalp 
Primary: 0-10 VAS current pain 
intensity, anchors "no pain" to "most 
extreme pain" 
When taken: 30 s, 15, 45, and 90 min 
poststimulation 
Secondary: none 
When taken: 30 s, 15, 45, and 90 min 
poststimulation 






Country of study: Germany 
Setting: pain clinic 
Condition: chronic pain (mixed 
musculoskeletal and neuropathic) 
Prior management details: "intractable" 
n = 12 
Age: 33-67 years, mean 51.3 (SD 12.6) 
Duration of symptoms: mean 2.7 (SD 2.4) 
Gender distribution: 6 M, 6 F 
Stimulation type: rTMS, circular coil for 
arm symptoms, double cone coil for leg 
symptoms                                                                                                             
Stimulation parameters: frequency 20 Hz; 
coil orientation not specified; 80% RMT; 
number of trains 20; duration of trains     
2 s; ITI not specified; total number of 
pulses 800; treatment duration 20 min 
Stimulation location: M1 (midline) 
Number of treatments: x 1 for each 
condition 
Control type: coil angled 45º away from 
the scalp 
Primary: 0-100 mm VAS pain intensity, 
anchors "no pain" to "unbearable pain" 








Country of study: Japan 
Setting: laboratory 
Condition: neuropathic pain (mixed central 
and peripheral) 
Prior management details: intractable 
n = 13 
Age: 29-76 years, mean 59.4 
Duration of symptoms: 2-35 years, mean 
10.2 (SD 9.7) 
Gender distribution: 7 M, 6 F 
Stimulation type: rTMS figure-of-8 coil 
Stimulation parameters: 
Condition 1: frequency 10 Hz; coil 
orientation not specified; 90% RMT; 
number of trains 5; duration of 
trains 10 s; ITI 50 s; total number of 
pulses 500 
Condition 2: frequency 5 Hz; coil 
orientation not specified; 90% RMT; 
number of trains 10; duration of 
trains 10 s; ITI 50 s; total number of 
pulses 500 
Condition 3: frequency 1 Hz; coil 
orientation not specified; 90% RMT; 
number of trains 1; duration of 
trains 500 s; total number of pulses 500 
Condition 4: sham, coil angled 45º from 
scalp with synchronised electrical scalp 
stimulations to mask 
sensation 
Stimulation location: M1 over the 
representation of the painful area 
Number of treatments: 1 for each 
condition 
Primary: VAS pain, anchors not 
specified 
When taken: 0, 15, 30, 60, 90, and 180 
minutes poststimulation 
Secondary: none 






(for 1 Hz only), 





Country of study: USA 
Setting: not reported, likely laboratory 
Condition: fibromyalgia 
Prior management details: "moderate to 
severe despite current and stable treatment 
regime" 
n = unclear, abstract report (Schneider 
2012 (see Tzabazis 2013)) stated 45, but 
full paper stated 16 
Age mean (SD): 53.2 (8.9) years 
Duration of symptoms, years mean (SD): 
not reported 
Gender distribution: 14 F, 2 M 
Stimulation type: rTMS 4-coil 
configuration 
Stimulation parameters: frequency 1 Hz; 
no of trains not reported; duration of 
trains not reported; ITI 
not reported, intensity 110% RMT, total 
number of pulses per session 1800, 
stimulation duration 30 min 
Stimulation location: targeted to the 
anterior cingulate cortex 
Number of treatments: 20, x 1 daily 
(working days) for 4 wks 
Control type: sham coil 
Primary: BPI average pain last 24 h, 
NRS, anchors not reported 
When taken: end of treatment, 4 wks 
post-treatment 
Secondary: FIQ 
Short 201138 Parallel RCT Country of study: USA 
Setting: laboratory 
Condition: fibromyalgia 
Prior management details: naive to TMS 
n = 20 
Age mean (SD): active group 54.2 (8.28) 
years, sham group 51.67 (18.19) years 
Duration of symptoms, years mean (SD): 
active group 12.1 (7.75), sham group 10.10 
(12.81)         
Gender distribution: 84% F 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation parasagittal, number of 
trains 80; duration of trains 5 s; ITI 10 s, 
intensity 120% RMT, total number of 
pulses per session 4000 
Stimulation location: L DLPFC 
Number of treatments: 10, x 1 daily 
(working days) for 2 wks 
Control type: sham coil 
Primary: pain VAS; 0 = "no pain", 10 = 
"worst pain" 
When taken: after 1 and 2 wks of 
treatment, then 1 wk and 2 wks 
posttreatment 
Secondary: FIQ, BPI function scale 
Tekin 201439 Parallel RCT Country of study: Turkey 
Setting: Rehabilitation outpatient unit 
Condition: fibromyalgia 
Prior management details: no analgesic use 
for 1 month prior to enrolment 
n = 51 
Age mean (SD): active group 42.4 (78.63) 
years, sham group 46.5 (8.36) years 
Duration of symptoms: mean (SD) active 
group 10.81 (6.31) years, sham group 
13.33 (6.65) 
Gender distribution: 47 F, 4 M 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation 45º angle from the 
midline, 100% RMT number 
of trains 30; duration of trains 5 s; ITI 12 
s; total number of pulses 1500 
Stimulation location: M1 midline, no 
neuronavigation 
Number of treatments: 10 sessions daily - 
unclear whether only work days 
Control type: sham coil - same sound and 
appearance, no control for sensory cues 
Primary: pain NRS anchors 0 = no 
pain, 10 = most severe pain 
When taken: end of intervention 
Secondary: WHQoL-BREF 




Parallel RCT Country of study: USA 
Setting: not reported 
Condition: burning mouth syndrome 
Prior management details: not reported 
n = 26 
Age mean (SD): active group 63.36 (10.78) 
years, sham group 64.42 (8.35) years 
Duration of symptoms, mean (SD): active 
group 61.57 (32.10) months, sham group 
65.58 (55.52) 
Gender distribution: active group 93% F, 
sham group 92% F 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation not specified, 100% RMT, 
number of trains 
10; duration of trains 5 s; ITI 10 s; total 
number of pulses 3000 
Stimulation location: L DLPFC 
Number of treatments: 10 x 1 daily on 
work days 
Control type: sham coil - same sound and 
appearance and sensory cues 
Primary: pain NRS anchors 0 = no 
pain, 10 = extreme amount 
When taken: end of stimulation and 15, 
30, 60 days after start of treatment 
Secondary: AEs 
Yagci 201441 Parallel RCT Country of study: Turkey 
Setting: not reported 
Condition: fibromyalgia 
Prior management details: no improvement 
in cases of using medical treatment for 
fibromyalgia for at 
least 3 months 
n = 28                                  
Age mean (SD): active group 45.25 (9.33) 
years, sham group 43 (7.63) years 
Duration of symptoms, mean(SD): active 
group 53 (29.15) months, sham group 
54.92 (30.44) 
Gender distribution: all F 
Stimulation type: rTMS 
Stimulation parameters: frequency 1 Hz; 
coil orientation not reported, 90% RMT, 
number of trains 20; 
duration of trains 60 s; ITI 45 s; total 
number of pulses 1200 
Stimulation location: L M1, no 
neuronavigation 
Number of treatments: 10 sessions, 
wkdays for 2 wks 
Control type: sham coil - same sound and 
appearance, no control for sensory cues 
Primary: pain NRS anchors 0 = no 
pain, 10 = maximum pain imaginable 
When taken: end of intervention, 1 
month, 3 months 
Secondary: FIQ, AEs 




Parallel RCT Country of study: Turkey 
Setting: rehabilitation unit 
Condition: post-SCI below lesion 
neuropathic pain 
Prior management details: pain that is 
resistant to pharmacological 
(anticonvulsants, antidepressants, 
narcotics) and interventional treatments 
n = 17 
Age mean (SD): active group: 40 (5.1) 
years, sham group 36.94 (8) years 
Duration of symptoms mean (SD): active 
group 32.3 (25.9) months, sham group 35.4 
(17.9) 
Gender distribution: all M 
Stimulation type: rTMS 
Stimulation parameters: frequency 10 Hz; 
coil orientation handle pointing 
posteriorly, number of trains 
30; duration of trains 5 s; ITI 25 s; total 
number of pulses 1500 
Stimulation location: M1 midline 
Number of treatments: daily for 10 
wkdays 
Control type: coil angled away - same 
sound and appearance, did not control 
for visual or sensory cues 
Primary: pain NRS anchors 0 = no 
pain, 10 = worst pain imaginable 
When taken: end of intervention, 6 
wks, 6 months postintervention 
Secondary: none relevant 
Visual analogue scale (VAS), Numeric rating scale (NRS), Leeds assessment of neuropathic symptoms and signs (LANSS), World Health Organization Quality of Life – BREF 
(WHQoL-BREF), rTMS (repetitive transcranial magnetic stimulation), Brief pain inventory (BPI), Fibromyalgia Impact Questionnaire (FIQ), rTMS (repetitive transcranial 
magnetic stimulation), Resting motor threshold (RMT), Hz (Hertz), Dorsolateral prefrontal cortex (DLPFC), Adverse events (AE) 
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APPENDIX E: ONGOING STUDIES 
Opioid Use Disorder 
NCT Number Title Status Conditions Interventions Completion 
Date 
NCT03653169 Use of Transcranial Magnetic Stimulation to 
Reduce Craving for Individuals With Opioid 
Use Disorder Taking Buprenorphine 
Enrolling by 
invitation 
Opioid-use Disorder TMS 7/1/2020 
NCT04231708 Effects of Pharmacological Stress and rTMS 
on Executive Function in Opioid Use Disorder 
Not yet recruiting Opioid Use Disorder rTMS + 
pharmacotherapy 
12/31/2022 
NCT04181515 Using rTMS to Explore Neural Mechanisms of 
Stress-Induced Opioid Use 
Not yet recruiting Opioid-use Disorder rTMS + 
pharmacotherapy 
6/1/2025 
NCT04336293 sTMS for Substance Use-disordered 
Veterans 
Not yet recruiting Opioid Addiction sTMS 5/31/2022 
NCT03821337 Transcranial Magnetic Stimulation (rTMS) as 
a Tool to Decrease Pain and Improve 
Functioning 
Active, not recruiting Opioid Use Disorder rTMS 5/31/2021 
NCT03653169 Use of Transcranial Magnetic Stimulation to 
Reduce Craving for Individuals With Opioid 
Use Disorder Taking Buprenorphine 
Enrolling by 
invitation 
Opioid Use Disorder TMS 7/1/2020 
NCT04231708 Effects of Pharmacological Stress and rTMS 
on Executive Function in Opioid Use Disorder 
Not yet recruiting  Opioid Use Disorder rTMS + 
pharmacotherapy 
12/31/2022 
NCT04181515 Using rTMS to Explore Neural Mechanisms of 
Stress-Induced Opioid Use 
Not yet recruiting Opioid-use Disorder rTMS + 
pharmacotherapy 
6/1/2025 
NCT04336293 sTMS for Substance Use-disordered 
Veterans 
Not yet recruiting Opioid Addiction sTMS 5/31/2022 
NCT03804619 Accelerated Intermittent Theta-Burst 
Stimulation for Opiate Use Disorder 
Not yet recruiting  Opiate Dependence, 
Depression 
rTMS (theta burst) 12/1/2022 
NCT04432493 Using Combined EEG and Non-invasive 
Brain Stimulation to Examine and Improve 
Reward Functioning in Opioid Use Disorder 
Recruiting Opioid-use Disorder rTMS 3/31/2022 
NCT04157062 An Open-Label Trial of Repetitive 
Transcranial Magnetic Stimulation for Opioid 
Use Disorder 
Recruiting Opioid-use Disorder rTMS 10/1/2021 
NCT03229642 Repetitive Transcranial Magnetic Stimulation 
in Patients With Opioid Use Disorders 
Recruiting Opioid Dependence rTMS 7/31/2020 
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NCT03538444 Repetitive Transcranial Magnetic Stimulation 
for Opiate Use Disorder 





NCT Number Title Status Conditions Interventions Completion 
Date 
NCT01806168 rTMS in the Treatment of PTSD Active, not recruiting PTSD rTMS 3/1/2019 
NCT02158663 Study Testing if Fast or Slow rTMS is Better 
for the Treatment of Posttraumatic Stress 
Disorder (PTSD) 
Completed PTSD/Depression rTMS 3/14/2019 
NCT02584894 Potentiation of Trauma Exposure in Post-
traumatic Stress Disorder by Repeated 
Transcranial Magnetic Stimulation 
Completed PTSD rTMS 4/17/2020 
NCT03932773 Multi-site Confirmatory Efficacy Treatment 
Trial of Combat-related PTSD 
Recruiting PTSD rTMS + cognitive 
processing therapy 
7/31/2023 
NCT03114891 Accelerated TMS to a Novel Brain Target in 
MDD and PTSD 
Recruiting PTSD/Depression rTMS (theta burst) 5/1/2021 
NCT04325087 Reduction of Trauma-induced Intrusions and 
Amygdala Hyperreactivity Via Non-invasive 
Brain Stimulation 
Recruiting PTSD rTMS (theta burst) 5/30/2020 
NCT00134446 Transcranial Magnetic Stimulation for Post-
Traumatic Stress Disorder 
Unknown status PTSD TMS  
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Traumatic Brain Injury (TBI) 
NCT Number Title Status Conditions Interventions Completion 
Date 
NCT03819608 Neuromodulation and Neurorehabilitation for 
mTBI Plus PTSD 
Recruiting mTBI/PTSD rTMS 3/1/2024 
NCT03523507 fMRI-neuronavigated rTMS Treatment for 
Symptoms of Depression Associated With 
Concussive TBI in the Military Population 
Recruiting TBI/Depression rTMS 2/1/2022 
NCT02458521 Transcranial Magnetic Stimulation (TMS) to 
Treat mTBI and PTSD 
Unknown status TBI/PTSD rTMS 5/1/2019 
 
Pain 
NCT Number Title Status Conditions Interventions Completion 
Date 
NCT03576781 Developing rTMS Treatment Strategies for 
Pain in Opiate Dependence 
Completed Chronic Pain, Opioid 
Dependence 
rTMS (theta burst) 11/12/2019 
NCT03576781 Developing rTMS Treatment Strategies for 
Pain in Opiate Dependence 
Completed Chronic Pain, Opioid 
Dependence 
rTMS (theta burst) 11/12/2019 
NCT03994991 Transcranial Magnetic Stimulation (TMS) for 
Thoracic Surgery 
Not yet recruiting Chronic Pain TMS 8/1/2022 
NCT03984201 Accelerated Theta Burst in Chronic Pain: A 
Biomarker Study 
Not yet recruiting Chronic Pain rTMS (theta burst) 8/1/2023 
NCT04203199 H-coil TMS to Reduce Pain: A Pilot Study 
Evaluating Relative Efficacy of the H1 vs H7 
Coil 
Not yet recruiting Chronic Pain, Opioid Use rTMS 7/1/2022 
NCT02687360 Imaging the Effects of rTMS on Chronic Pain Recruiting Chronic Pain, Opioid 
Dependence 
rTMS 10/1/2021 
NCT02572726 An Exploration of the Neuroplasticity of 
Endogenous Analgesia in Health and 
Chronic Pain 
Recruiting Pain | Fibromyalgia rTMS 12/1/2020 
NCT03681769 Developing Brain Stimulation as a Treatment 
for Chronic Pain in Opiate Dependent 
Recruiting Chronic Pain, Opiate 
Dependence 
rTMS (theta burst) 7/1/2021 
NCT04283643 Noninvasive Brain Stimulation for Pain Relief Recruiting Acute Pain, Chronic Pain TMS 4/1/2021 
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NCT02687360 Imaging the Effects of rTMS on Chronic Pain Recruiting Chronic Pain, Opioid-use 
Disorder 
rTMS 10/1/2021 
NCT04156802 Project Relief: Developing Brain Stimulation 
as a Treatment for Chronic Pain 
Recruiting Chronic Pain, Opioid Use rTMS (theta burst) 12/1/2021 
NCT03973788 Effects of Repetitive Transcranial Magnetic 
Stimulation on Pain Thresholds in Patients 
With Chronic Low Back Pain 
Recruiting Low Back Pain rTMS 8/31/2020 
NCT03076294 Repetitive Transcranial Magnetic Stimulation 
Associated With Manual Therapy in Knee 
Osteoarthritis Pain 
Unknown status Pain, Knee Osteoarthritis TMS 3/1/2019 
 
Alcohol Use Disorder 
NCT Number Title Status Condition Intervention Completion 
Date 
NCT03995173 Pilot rTMS for AUD+mTBI Recruiting Alcohol Use Disorder, 
mTBI, PTSD 
rTMS 11/1/2020 
NCT04043442 rTMS Target Identification for Functional 
Disability in AUD+mTBI 
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Comparator TMS Protocol:  
Location 
Frequency (Hz) 
Intensity (% RMT) 
Sessions 






a diagnosis of 
diabetic 
neuropathy 

















Location: Precentral motor 
cortex (hemisphere contralateral 
to pain) 
Frequency: 20 Hz 
Intensity: 80-90% RMT 
Sessions: 5 session (daily) 
Decrease in pain severity 
at 1 wk from baseline 
(p<0.05) in both groups, 










upper limb or 
facial 
neuropathic 
pain for at 
least 1 year 
Age: 18-80 
% male: NR 








Location: Hand or facial motor 
cortex 
Frequency: 20 Hz 
Intensity: 90% RMT 
Sessions: 3 sessions (2 active, 
1 sham, separated by 2 wks) 
rTMS targeted over the 
hand motor cortex had 
greater pain relief than 
rTMS targeted over facial 
cortex face rTMS 








chronic (> 3 
months) CNP 
due to stroke 









Location: Anterior cingulate 
cortex (ACC) or posterior 
superior insula (PSI) 
Frequency: 10 Hz 
Intensity: 90% RMT 
Sessions: 16 sessions (daily for 
5 days (induction) then 1 
session/wk for 11 wks) 
NRS score was not 
significantly 
different between groups 
at any point during  the 
study. 
Active dTMS 
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Age: 55.02 
% male: NR 
% white: NR 













% male: 64.6 








Location: Primary motor cortex 
(M1) targeting part of the body 
with the worst pain  
Frequency: 5 Hz 
Intensity: 90% RMT 
Sessions: 5 sessions (daily), 
then 1 session/wk for 4 wks 
(responders only - open-label) 
Pain improvement not 
significantly different 
(p=0.58) between the 
rTMS (-8.0) and sham    
(-9.2) during the daily 
sessions. No difference 
in number of responders 
(≥ 10mm decrease VAS) 
between rTMS (31%) 
and sham (37%). The 
patients enrolled in the 
continuous wkly rTMS 
achieved more pain relief 
in with rTMS compared 
with the sham (p<0.01). 
No difference in 
quality of life 












% male: 64.6 






ham iTBS: coil 
turned away 
from skull at 
90° 
Location: Ipsilateral hemisphere 
Frequency: 50 Hz 
Intensity: 80% RMT  
Sessions: 5 sessions (daily) 
S-LANSS decreased 
more in iTBS (-4.53) vs 
sham (-0.8) (p=0.002). 
NRS decreased more in 
iTBS (-2.13) vs sham (-
0.86) (p=0.029). 
















% male: 63.3 




sham rTMS Location: Primary motor cortex 
contralateral to the patient's 
pain  
Frequency: 20 Hz 
Intensity: 80% RMT 
Sessions: 8 sessions (4 
sessions each stimulation) over 
9 wks (3 wks between sessions 
and 8 wk washout) 
Percent of pain relief 
(%R) was greater after 
rTMS phase (33.8%) 
compared to sham phase 
(13%). 54% (rTMS) vs 
21% (sham) achieved 
≥30% pain relief and 
35% (rTMS) vs 12% 
(sham) achieved ≥50% 
pain relief. Significant 
decrease in VAS after 
rTMS phase but not 
sham phase. 
Quality of life 
(EQ5-D) did not 
change over time 
or between groups. 
One patient 


















% male: 88 
% white: NR 
rTMS 





Sham rTMS: coil 
turned away 
from skull at 90° 
Location: Left primary motor 
cortex 
Frequency: 10 Hz 
Intensity: 80% RMT 
Sessions: Daily sessions for 6 
wks, with one-day interval per 
wk 
Pain intensity decreased 
from baseline to 6 wks in 
rTMS group (5 vs 1.5* 
NRS) and sham group 
(4.5 vs 3* NRS). Pain 
intensity decreased more 
in rTMS group compared 
to sham and the 
difference became 
significant at wk 2. 
*Estimated from Figure 4 




















CRPS and had 
pain greater 
than 3/10 





% male: 9.5 






1 TMS session 
group vs 5 TMS 
session group 
 
Location: targeted over motor 
cortex to stimulate CPRS 
affected region 
 
Frequency: 50 Hz (iTBS) then 
10 Hz 
Intensity: 70% (iTBS) then 80% 




pain reduction after 1 wk 




(≥30% reduction in pain 
from baseline): 60% of 
participants with 1 
session responded at wk 
1. 58% and 50% of 
participants responded at 
wks 1 and 2 with 5 
sessions. 






























% male: 0 (all 
female) 










Frequency: 10 Hz 
Intensity: NR 
Sessions: 15 sessions (every 
other day for 1 month) 
Significant decrease in 
mean VAS score with 
rTMS immediately after 
treatment (-20) and at 1 
month (-24.3) and with 
injection therapy 
immediately after 
treatment (-25.2) and at 
1 month (-49). Injection 
therapy had lower pain 
scores at baseline 
Significant 





score with rTMS (-
7.29) and injection 
therapy (-30.7) at 1 
month. Injection 
therapy had lower 
NR 
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(p=0.002) and 1 month 
compared to rTMS 
(p<0.001). 
FIQR scores at 1 















% male: 26.3 






coil at 0.1 Hz, 
1% RMT 
Location: left primary motor 
cortex (M1) or Left DLPFC 
Frequency: 10 Hz  
Intensity: 90% RMT 
Sessions: 15 sessions 
(sessions/wk for 3 wks) 
Significant improvements 
from baseline in VAS 
score in M1 (-2.8), 
DLPFC (-2.2) and sham 
(-1.7). Decrease in VAS 
significantly greater in 
Group M1 vs sham 
(p=0.028), but not 
DLPFC vs sham (p=.238) 




baseline in FIQ 
score in M1 (-
14.7), DLPFC (-
12.3) and sham (-
12.4). No 
differences in 




baseline in SF-36 
physical 
functioning score in 
M1 (25), DLPFC 
(19.5) and sham 
(4). SF-36 physical 
functioning 
improvement 
greater in M1 vs 
sham (p=0.002), 
and DLPFC vs 
sham (p=.004), but 















% male: 0 





coil at 1% RMT 
Location: Left DLPFC 
Frequency: 10 Hz 
Intensity: 90% RMT 
Sessions:  14 sessions (5 
days/wk for 2 wks (induction 
phase), then 1 session/wk for 4 
wks) 
There was no significant 
difference in VAS-pain 
over time or between 
groups (p>0.05). 
FIQ decreased at 
wk 2 vs baseline in 
rTMS group but not 
sham group. No 
differences 
compared to 
baseline at wk 6 in 
either group. No 



















% male: 26.3 








Location: Left DLPFC 
Frequency: 10 Hz  
Intensity: 100% RMT 
Sessions: 10 sessions (5 
sessions/wk for 2 wks) 
Decrease in pain score 
(VAS) with rTMS (wk 2 
vs wk 1, -0.7, p=0.021), 
but not with sham (wk 2 
vs wk 1, +0.1, p=0.585). 
No significant difference 
between groups at wk 1 























% male: 8.3 








Location: Left DLPFC 
Frequency: 10 Hz 
Intensity: 120% (RMT) 
Sessions: 20 sessions (5 
consecutive session/wk for 4 
wks) 
 
Pain improved at 1 
month vs baseline in 
both rTMS and sham 
groups on all pain 
measures. No significant 
differences between 
groups was observed. 
rTMS group significantly 
more likely to respond 
(achieve a minimum 30% 
improvement in pain 
intensity ratings) 7 rTMS 
vs 1 sham (p=0.024). 
Both groups 
improved at 1 
month vs baseline 































% male: 8.9 

















Location: Left DLPFC 
Frequency: 10 Hz 
Intensity: 90% RMT 
 
Sessions:  14 sessions (5 
days/wk for 2 wks (induction 
phase), then 1 session/wk for 4 
wks) 
There was no significant 
difference in VAS-pain 
over time or between 
groups (p>0.05). 
FIQ improved after 
therapy (wk 14) 
and at 6 month 
follow-up for both 
rTMS and sham 
groups (p<0.001). 

















with history of 
headache >15 
days a month for 
3 months or 
more 
Age: 35.7 
% male: NR 
% white: NR 
rTMS 
4 Wks after 
completion 




Location: Right DLPFC 
Frequency: NR 
Intensity: 110% RMT 
Sessions: 20 sessions (5 
sessions/wk for 4 wks) 
NRS score decreased 
significantly (P<0.001) in 
the rTMS group 




than sham group in 
Headache Impact 
Test-6 (HIT-6) 
(p<0.001), but not 







patients with a 
diagnosis of 
migraine with or 
without aura 














Location: Left DLPFC 
Frequency: 50 Hz  
Intensity: 80 
Sessions: 10 session (2x/day for 
5 days) 
There was a greater 
decrease in frequency, 
duration, and severity of 
migraine in the active 
group compared to the 
sham group over the 
study period (p<0.001). 
There was a 
greater decrease in 
MIDAS score 
compared to sham 












Abbreviations: rTMS, (Repetitive Trancranial Magnetic Stimulation), Dorsolateral prefrontal cortex (DLPFC), World Health Organization Quality of Life assessment (WHO 
QOL), Migraine Disability Assessment Score (MIDAS), Chronic tension-type headache (CTTH), Fibromyalgia Impact Questionnaire (FIQ), Numerical rating scale (NRS), 
Resting motor threshold (RMT), Hertz (Hz) 
  



















TMS Protocol:  
Location 
Frequency (Hz) 

















% male: 100 








Location: bilateral (left and 
right) or right DLPFC 
Frequency: 20 Hz 
Intensity: 100 % RMT 
Sessions: 10 session (3 
sessions/wk for 2 wks; 2 
sessions/wk for 2 wks) 
Greater proportion of 
responders (≥ 2 std from 
mean PCL) in rTMS 
(bilateral (62.5%) and 
unilateral (41.2%)) 
groups compared to 
sham (0%) (p=0.0001) 
and no difference was 
found between bilateral 
and unilateral groups. 
Significant mean 
improvement in PCL in 
unilateral and bilateral 
rTMS vs sham after all 
sessions. 
NR 2 patients 
withdrew due to 















% male: 87.5 








Location: Right or left 
prefrontal cortex 
Frequency: 10 Hz 
Intensity: 120% RMT 
Sessions: 8 (1 session/wk 
for 8 wks) 
Reduction in CAPS 
scores was 55% (90% 
CI 18.5-53.5) with rTMS 
compared to 40% (90% 
CI 13.6-73.0) with sham 
at session 5. 













% male: 76.9 
% white: NR 






TMS + traumatic 
imagery 
Location: Prefrontal cortex 
Frequency: 20 Hz 
Intensity: 120% 
Sessions: 12 sessions (3 
sessions/wk for 4 wks) 
CAPS score improved 
significantly in rTMS + 
trauma imagery group (-
27, p<.0.05), but not in 
rTMS + positive imagery 
group (-10, p>.0.05), or 
sham group (-10, 
p>0.05) 
NR A few patients 
had mild 
headaches 





















Location: right DLPFC 
Frequency: 1 Hz 
Intensity: 110% motor 
threshold 
Sessions: 12 sessions 
(1session/wk for 12 wks) 
Total CAPS score had a 
greater decrease from 
baseline in rTMS (-48) 
compared to sham (-36) 
group (p<0.023) 
NR 3 participants 
withdrew due to 
headaches (2 













10 Hz. vs 1 Hz 
rTMS 
Location: Right DLPCF 
Frequency: 1 Hz or 10 Hz 
Intensity: 110% RMT  
Sessions: 36 sessions 
(timing NR) 
CAPS response: 29% 1 
Hz vs 31% 10 Hz 
(p=1.0) after 30 
sessions 
CAPS remission: 21% 1 
Hz. vs 33% 10 Hz 
(p=0.67) after 30 
sessions 
Improved CAPS score 
with 1 Hz (-9.4) and `0 
Hz (-10.9) rTMS after 30 
sessions. No significant 
difference between 
groups. 




(IPF) score with 
1 Hz (-.4) or 10 
Hz (-0.5) rTMS 
after 30 
sessions 
There were no 






treatment at the 













% male: 17.1 




sham coil (1 Hz 
or 10 Hz) 
mimicking 
sounds 
Location: Right DLPFC 
Frequency: 1 Hz or 10 Hz 
Intensity: 120% RMT 
Sessions: 10 sessions (5 
sessions/wk for 2 wks) 
PTSD symptoms 
improved at the end of 
treatment with 1 Hz 
rTMS (p=0.021) 
compared to sham, but 
not with 10 Hz rTMS 
(p=.065) compared to 
sham. There was a 
significant time x 
treatment effect over the 
3 month follow-up 
(p=0.046). 
NR On participant 










% male: 37.5 




coil turned away 
from skull at 90° 
Location: right prefrontal 
cortex 
Frequency: 1 Hz 
Intensity: 100% RMT 
Sessions: 15 sessions (5 




for all groups (p<0.001) 
but no significant effect 
of treatment group 
(p=0.147). Significant 
NR Mild adverse 
effects, such as 
headache (3 
rTMS, 2 sham), 
dizziness (1 
rTMS, 1 sham), 
and difficulty 
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Location: right DLPFC 
Frequency: 50 Hz 
Intensity: 80% RMT 
Sessions: 10 sessions (5 
consecutive sessions/wk for 
2 wks) 
Overall, 47.8% of 
patients had clinical 
relapse (1 patient (2.1%) 
overdose death, 3 
patients (6.5%) inpatient 
hospitalization, and 18 
patients (39.1%) TMS 
retreatment). Fewer 
patients in active iTBS 
group (33.3%) had 
relapse compared to 
sham (63.6%) (OR 
relapse = 3.5, 95% CI 






PTSD and MDD 
 
Age: 51 
% male: 84.8 
%: 88 



















Sessions: 20 (5 sessions/wk 
for 4 wks) 
All participants 
demonstrated significant 
reductions in PTSD and 
MDD symptoms (p< 
0.001). No significant 
difference in PTSD 
symptoms (PCL total 
score) (p=0.083) or 
MDD symptoms (QIDS-
SR total score) 
(p=0.091) between 
groups, but greater 
improvement in "PTSD 
threshold symptoms" in 
sTMS group (p=0.011). 
















% male: 84 








Location: right DLPFC 
Frequency: 50 Hz 
Intensity: 80% RMT 
Sessions: 10 sessions (5 
consecutive sessions/wk for 
2 wks) 
No difference in PTSD 
symptoms (CAPS) 
between groups 
(p=0.31) after treatment 
(2 wks). At 1 month 
(after unblinded phase) 
iTBS had greater PTSD 
symptom improvement 









(p=0.04) after 2 
NR 
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(p<0.001). More patients 
responded (≥ 12 point 
CAPS reductions) with 
iTBS (81%) compared to 
sham (67%) (p<0.001).  









% male: 90 








Location: Right DLPFC 
Frequency: 1 Hz 
Intensity: 90% RMT 
Sessions: 10 sessions (5 
consecutive days/wk for 2 
wks) 
rTMS group had 
significant reduction in 
PTSD symptoms 
compared with sham 
after treatment (2 wks) 
(p=0.009 CAPS, 
p=0.002 PCL). CAPS 
scores remained 
significantly improved 
from baseline at 2 
months post-treatment, 
but 6/10 participants had 
≥ 10 point worsening in 
PTSD symptoms from 
post-treatment to 2 
months). 
NR NR 
Abbreviations: Post-traumatic stress disorder (PTSD),  PTSD checklist-military version (PCL-M), Clinician Administered PTSD Scale (CAPS), PTSD Checklist (PCL), rTMS 
(repetitive Transcranial Magnetic Stimulation), Intermittent theta-burst stimulation (iTBS), Dorsolateral Prefrontal Cortex (DLPFC), Resting motor threshold (RMT), Operation 
Iraqi Freedom / Operation Enduring Freedom (OIF/OEF), Migraine Disability Assessment Score (MIDAS), Adverse events(AE) 
 
  


















TMS Protocol:  
Location 
Frequency (Hz) 










Adults with mild 
TBI and pain 
lasting at least 6 
months 
Age: 42.6 
% male: 50 




coil turned away 
from skull at 90° 
Location: Primary motor 
cortex 
Frequency: 10 Hz 
Intensity: 90% RMT 
Sessions: 10 sessions (5 
per wk for 2 wks) 
Changes in NRS 





lower in rTMS group 
compared to sham 




increased more in 
rTMS group 
compared to sham 
group at each time 
point, but SF-36 
mental component 










People with TBI (≥ 















turned away at 
45° 
Location: Left or right 
DLPFC 
Frequency: 1 Hz (right), 
10 Hz (left) 
Intensity: 110% RMT 
Sessions: 20 sessions 





for both groups 




Trail Making Test 







to sham (72% 







Patients with TBI 





% male: 69 










Location: Right DLPFC 
Frequency: 1 Hz 
Intensity: 100% RMT 
Sessions: 10 sessions (5 
consecutive sessions/wk 




symptoms after rTMS 
(p<0.05) but not after 
sham. Improvement 
with rTMS vs sham: 
MADRS (-6.86 vs -
0.34), 
Improvement in 
function after rTMS 
but not after sham. 
Improvement with 
rTMS vs sham: 
TMT (-6.03 vs -
1.20), and SCWT (-
19.99 vs -3.00). 
No adverse 
effects reported. 






Veterans with mild 
traumatic brain 




% male: 87.5 
% white: NR 






turned away at 
180° 
Location: Left motor 
cortex 
Frequency: 10 Hz 
Intensity:  80% RMT 
Sessions: 3 sessions 
(within 1 wk) 
More patients in 
rTMS group had ≥ 
50% headache 
reduction compared 
to sham (58.3% vs 
16.6%, p=0.035). 




in rTMS group at 4 
wks while sham did 
not. 




at wks 1 or 4 
between groups. 
Significant 
interaction of visit 
and treatment at 1 
wk, with an 
increase in CPT 
score with rTMS, 
but decrease in 






















% male: 79.3 
% white: NR 






turned away at 
180° 
Location: Left prefrontal 
cortex 
Frequency: 10 Hz  
Intensity: 80% RMT 
Sessions: 4 sessions 
(within 1 wk) 
Signification 
reduction (p<0.0001) 
in average daily 
persistent headache 
intensity with rTMS 
but not sham at 1-wk 
(-25.3% vs -<1%) 
and 4-wks (-23% vs -
2.3%). Significant 
reduction (p=0.009) 
in % of patients no 
longer experiencing 
persistent headaches 
with rTMS but not 
sham at 1-wk (50% 
vs 7%) and 4-wks 
(57% vs 29%). 
No overall 
interaction 
between group and 



















% male: NR 












Mental and physical 
comfort significantly 
improved with rTMS 















% male: 90 








Location: Left DLPFC 
Frequency: 10 Hz 
Intensity: 110% RMT 
Sessions: 10 sessions 
(daily) 
No differences in 
executive function 
between groups or in 




days compared to 
















% male: 53.3 








Location: Right DLPFC 
Frequency: 1 Hz 
Intensity: 110% RMT 
Sessions: 20 session (5 
consecutive sessions/wk 




groups in changes in 
HAM-D scores or on 
rates of remission or 
response. HAM-D 
scores varied widely, 
favoring rTMS at 
some time points (8 
and 16 wks) and 
sham at others (4 




and favored rTMS 
for some measures 




























% male: 73.3 
% white: NR 












Location: Left and right 
DLPFC 
Frequency: 1 Hz (right), 
10 Hz (left) 
Intensity: 120% RMT 
Sessions: 20 sessions 
(over 5 wks) 
Mean MADRS 
improvement was 
greater with rTMS 
(56%) than with 
sham (27%). 
Hypothesis testing 
not completed due to 
study termination. 
No clear 




















% male: 10 









Location: Left DLPFC 
Frequency: 10 Hz 
Intensity: 70 % RMT 
Sessions: 10 sessions (5 
consecutive sessions/wk 
for 2 wks) 
Significant overall 
time effect for 
average headache 
severity (p=0.03) but 
no effect of treatment 
group at 1-month 
post-treatment. 
Significant time 
effect for quality of 
life (Quality of Life 
after Brain Injury 
(QOLIBRI), p = 
















Abbreviations: Numerical Rating Scale (NRS), Montgomery Asberg Depression Rating Scale (MADRS), Trail Making Test (TMT), Stroop Word Color Test (SCWT), Hamilton 
Depression Rating Scale (HAM-D), Dorsolateral prefrontal cortex (DLPFC), rTMS (repetitive transcranial magnetic stimulation), Traumatic brain injury (TBI), Quality of Life 
after Brain Injury (QOLIBRI), Montreal Cognitive Assessment (MoCA), Conner's Continuous Performance (CPT), Resting motor threshold (RMT), Hertz (Hz) 

















TMS Protocol:  
Location 
Frequency (Hz) 
Intensity (% RMT) 
Sessions 














% male: 100 
% white: NR 
rTMS 
90 days 
Wait list Location: Left DLPFC 
Frequency: 10 Hz or 1 
Hz 
Intensity: 100% RMT 
Sessions: 20 sessions 
over 28 days 
Craving scores decreased more in 
first 30 days in both 1 Hz (-25.3 
points) and 10 Hz groups (-29 points), 
compared to control (-11.6 points). All 
groups had significantly reduced 
craving score at 30, 60, and 90 days 
compared to baseline. No group had 
significant change in craving score at 
60 or 90 days compared to 30 days. 
None Mild side effects 
reported (dizziness, 
headache, neck pain, 











Age: range 30-54 
% male: 100 







skull at 90° 
Location: Left DLPFC 
Frequency: 10 Hz 
Intensity: 100% RMT 
Sessions: 5 sessions 
(daily) 
Craving score reduction of 20 points 
(60 vs 40) from baseline after rTMS 
(p=0.015) and 0 points (62 vs 62) 
from baseline after sham rTMS 
(p>0.05). 
None No subject reported 
any side effects 
Abbreviations: Repetitive transcranial magnetic stimulation (rTMS), Dorsolateral prefrontal cortex (DLPFC), Motor threshold (MT), Hertz (Hz), Resting motor threshold (RMT), 
Not reported (NR) 





Condition   Intervention  
 
Study follow-up 






One wk  
Pain intensity via verbal rating scale 
(VRS) 
Statistically significant difference was 
observed in the VRS score before 
and after the rTMS sessions with a 
median decrease of 3 points in the 
intensity of pain 
No serious side effects were 
noted and in particular no 
epileptic seizures were 
observed. Less than 1% of 










Percentage of pain relief (%R), 
duration of pain relief (DPR), 
numeric rating scale (NRS), 
neuropathic pain symptom inventory 
(NPSI), and pain relief score (PRS). 
%R was 28% and DPR (11 days after 
the first 4 sessions. After 12 months 
of treatment (15 sessions) a 
cumulative effect on %R (48%), DPR 
(20 days). This effect reached 
significance after 4 sessions and was 
further maintained over 12 months. 









Visual analogue scale (VAS) for pain  
intensity 
8/46 patients reported a significant 
level of pain relief (P < 0.001). 
31/48 patients in the cohort 










VNS scores for pain, Analgesic 
effect, Neuropathic Pain Symptom 
Inventory (NPSI) 
Analgesic response (pain intensity) 
decrease > 30% compared to 
baseline, observed in 39 patients 
(68%). 











Patient Global Impression of Change 75% reported improvement on the 
Patient Global Impression of Change 
with a reduction in both pain intensity 
and pain interference 
No serious adverse effects. 
50% of patients reported  










Numerical rating scale (NRS) for 
pain relief  
Decreased pain was observed on the 
NRS after treatment and at 1 and 8 
wks (P=0.019, P=0.006, P=0.042, 
respectively). 
Mild transient tension 
headache reported by 2 
patients. No adverse events 
or increase in pain occurred  








PTSD Checklist (PCL) and Inventory 
of Depressive Symptomatology, 
Self-Report (IDS-SR) for PTSD and 
MDD symptoms. 
Stimulation significantly reduced 
PTSD symptoms (PCL baseline 
mean ± SD score 52.2 ± 13.1 versus 
endpoint 34.0 ± 21.6; p<.001). MDD 
symptoms also improved significantly 
(IDSSR baseline 47.8 ± 11.9 to 
endpoint 30.9 ± 18.9; p<.001); 15 
patients (42.9%) demonstrated 
categorical response and 12 (34.3%) 
remitted. 
Four patients experienced 
serious adverse events; 3 
required hospitalization for 
worsening symptoms with 
suicidality, and 1 for 
suicidality and substance 
abuse. One patient withdrew 
due to exacerbation of 
migraine. Fourteen (40%) 
experienced at least mild 
activation of PTSD 
symptoms; all but 1 of these 











PTSD checklist (PCL-M),  Clinical improvements on the PCL-M 
were seen in all 16 patients, with an 
average pre-treatment score of 54.9 
and post-treatment score of 31.8  
(P < 0.001). 









Impact of Event Scale (IES), Beck 
Depression Inventory, Beck Anxiety 
Inventory 
Statistically significant decreases in 
IES hyperarousal scores (from 21.4+- 
4.7 to 19.0 +-4.2, p=0.02). No 
statistically significant differences 
between total IES scores, IES 
intrusion scores, IES avoidance 
scores, Beck Depression Inventory, 










PTSD checklist-Civilian (PCL-C) and 
Difficulties in Emotional Regulation 
Scale (DERS) 
PCL-C scores reduced by 51.99% +- 
27.24% overall (p<0.001). DERS 
scores improved by 36.02% +-
24.24% overall. 
No adverse events aside 
from transient headaches 








PTSD Checklist (PCL), Quick 
Inventory of Depressive 
Symptamatology (QIDS) 
Significant reduction in PTSD 
symptoms (p=0.003, effect size=1.12) 
and depression symptoms (p=0.005, 
effect size=1.09). 
No adverse events 









3 months  
Clinician-Administered PTSD Scale 
for DSM-5 (CAPS-5), Hamilton 
Depression Rating Scale (HAM-D) 
Reductions in both PTSD (effect 
size= -1.78) and depression (effect 
size=-1.16) symptom severity post-
treatment. Continued further modest 
decline at 3-month follow-up. 
No serious adverse events 
aside from mild to moderate 








Clinician-Administered PTSD Scale 
(CAPS), PTSD Checklist-Military 
(PCL-M), Treatment Outcome PSTD 
Scale (TOP-8) 
PCL-M scores significantly lower 
post-treatment (38.71 +- 13.91) and 
one wk post-treatment (33.29 +- 
16.62) than baseline (33.29 +-16.62). 
TOP-8 scores significantly lower post-
treatment (11.57 +-6.21) and one wk 
post-treatment (11.14 +-8.84) than 
baseline (24 +-5.23). Decrease in 
depression and anxiety symptom 
severity. 
No adverse events aside 






PCS Scale PCS scores declined on average by 
14.6 points (p=0.009) 
Two participants withdrew 
because of worsening 
symptoms. Side effects 
included increased 







Numerical rating scale (NRS) for 
pain relief  
Average pre and post-rTMS NRS 
scores were 5.50 +- 1.38 and 2.67 +- 
1.75, respectively. Average headache 
exacerbation frequency (episodes per 
wk) reduced by 78.97% (+- 19.88).  
None reported 
Abbreviations: Verbal rating scale (VRS), Duration of pain relief (DPR), Numeric rating scale (NRS), Neuropathic pain symptom inventory (NPSI), Pain relief score (PRS), Visual 
analogue scale (VAS), Visual numerical scale (VNS), Clinician-Administered PTSD Scale (CAPS), PTSD Checklist-Military (PCL-M), Treatment Outcome PSTD Scale (TOP-8), 
PTSD Checklist (PCL), Quick Inventory of Depressive Symptomatology (QIDS), Emotional Regulation Scale (DERS), Impact of Event Scale (IES), Difficulties in Emotional 
Regulation Scale (DERS), Self-Report (IDS-SR), Major depression disorder (MDD) 
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APPENDIX G: QUALITY ASSESSMENT TABLES 
QUALITY ASSESSMENT OF RCTS 
Author, 
Year 
Risk of bias from 
randomization process 










Risk of bias from 
missing outcome 
data 
Risk of bias in 
measurement of the 
outcome 


















groups at baseline in 
visual analog scale, 
fatigue severity scale, 
physical functioning, 









































Researchers and patients 









Unclear if blinding 
of rTMS provider 
Low 
 
Participants blind to 





No reported missing 
data. One 
participant  withdrew 































Unclear if blinding 
of rTMS provider 
Low 
 
Participants blind to 



























physiotherapists blind to 
allocation. Baseline 
characteristics similar, 
except control group had 
21% men while the 




























































others in the study. 
Low 
 





























random numbers in 
blocks of 10. Participants 









assessors blind to 
assignments. 




Participants blind to 
assignments. No flow 

























Alternate allocation. Says 
"double-blind", but limited 












21% had to be dropped 
out of the study, 




21% had to be 
dropped out of the 
study, no 
information on 































No flow diagram, but 











Unclear if outcome 













No information about 
randomization process or 
allocation concealment. 



















































































allocation function of 
EDC system. Participants 








































sequence of blocks was 
generated by a computer 
and concealed using 















condition as allocated 
(1 withdrew due to 
unrelated injury).  
Low 
 
No participants lost 
to follow-up. >95% 
completed follow-up 



















Randomization and data 
collection were 
performed using 
REDCap electronic data 
capture tools. Allocation 
concealment not 
described (but appeared 



















condition as allocated 






missing data (14% 
of each group lost to 
follow-up/ withdrew) 
but single imputation 
(last/baseline 
observation carried 






















data center determined 
the order of stimulation. 
Allocation concealed 
using unlabeled magnetic 
card that changed mode 








condition, but may 
have been able to 
distinguish 
between different 




than one type 
because crossover 













condition as allocated. 
Low 
 






















No baseline differences 






to treatment group. 











3 participants in 
rTMS group and 1 
from sham group 
withdrew during the 
trial. No description 



















conducted by statistician 
(unclear mechanism). 
Allocation concealment 
not described. No 
baseline differences 
between groups on 














25% withdrew or were 
lost to follow-up. 
High 
 
Moderate loss to 
follow up and use of 
last observation 





















unlabeled magnetic card 
that changed mode of 
operation of TMS device. 
Higher  CAPS score and 
lower depression score in 
experimental group (no 


















appear to have 




incomplete data. No 







































~10% of patients 
withdrew from each 
group, but all 
interventions delivered 
as allocated. Results 
presented for all 






Results provided for 




























recorded on cards and 
placed in sealed 
envelopes that were 
sequentially numbered by 
an investigator not 
involved with the 
participants. Baseline 
differences between 










but "were isolated 
from other study 
staff members and 










and outcomes for those 
who completed therapy 
versus those who 
withdrew, but  
differences were not 



























generated using a 
computer randomization. 
Assignments placed in 
envelopes prior to trial. 










~25% lost to follow up 







allocation were not 
analyzed (6); 
patients lost to 





















randomized by random 
sequence generation 
2:2:1:1 with allocation 
concealment by the 

















Minimal loss to 
follow-up/  
withdrawal, but 3-
month outcomes not 






















Random sequence and 
allocation concealment 
method not described. 




Patient blinded but 
provider unblinded 
(though provider 
was "blind to all 
subject information 
and blocked from 
communicating 
about subjects with 
raters. Prior to the 
study, the 
experimenter was 
trained to maintain 








treatment as allocated  





complete with the 


















Random sequence and 
allocation concealment 
method not described. 














Appears that all 
patients received 
treatment as allocated. 
Low 
 




























uninvolved in treatment 
delivery selected coil to 
conceal randomization. 


















suggests that all 
patients received 



























assigned, but no details 
on methods of 
randomization. Unclear 
allocation concealment. 
Appears that rTMS group 
may have more 
comorbidities, but no 














No information on 



















sequence. No baseline 
differences between 














































14% of patients 



















Evidence Brief: TMS for Conditions Other than Depression Evidence Synthesis Program 
64  
groups, except use of 
antidepressant 
medication. Unclear 
method of allocation 
concealment. 
assignment. 













concealed by sealed 
envelopes. No baseline 
differences between 











Flow diagram states 
that all subjects 
completed the trial. 
Low 
 

























sequence. No baseline 
differences between 



























carried out with 
relatively substantial 






























sequence. No baseline 
differences between 



























carried out, but 
relatively small 




























sequence. No significant 
differences between 
groups at baseline. 
Allocation concealed 

















(16.6%) did not 
complete study and 
were excluded from 
analysis. Complete 
case analysis 
carried out with 
relatively substantial 
























sequence. No baseline 
differences between 
groups, except for higher 
fatigue in control group. 

















imputed, but unclear 
use on imputations. 


























sequence. No baseline 
differences between 















2 subjects (15%) did 
not complete the 




No information on 





















sequence. No significant 
differences between 
groups at baseline (sham 
group older with less 
preventive medications). 
Allocation concealed 













Flow diagram states 
that all subjects 
completed the trial. 
Low 
 



























to treatment group. 









>80% followed-up at 
90 days. No 
description of 





























No information about 
blinding of participants 





No information on 
loss to follow-up or 
handling of missing 
data. 
Unclear 
Unknown if outcome 
assessors were 











Petrosino 2020 not rated, same study as Philip 2019 
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QUALITY ASSESSMENT OF COHORT STUDIES  
Author Year Selection bias  Bias in 
classification of 
interventions  




Bias due to 
measurement of 
outcomes  
Bias due to 
confounding 
Bias due to 
missing 
data 

















were matched in 
age, sex, and 
disease duration, but 
no data presented. 
































on disease severity, 
unclear balance of 
disease severity 
















Manko, 201374 High 
 
Unclear how patients 
were selected into 












groups. No other 


























on patient and 
disease 
characteristics and 
unclear balance of 
characteristics 
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Gaertner, 201849 Unclear 
 
Minimal info on how 
participants were 
selected. Unclear if 
groups were 






groups. Unclear if 
patient or disease 
characteristics 








groups. 19% did 

















on patient and 
disease 
characteristics and 
unclear balance of 
characteristics 
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APPENDIX H: STRENGTH OF EVIDENCE 
Author, Year 
N 
Primary Outcome(s) Findings Quality Strength of Evidence 




Pain: VAS, NRS  Both groups demonstrated significant pain reduction after 1-wk 
posttreatment; but no differences between groups. 
High Very Low SOE 
It is unclear whether TMS may 
improve pain compared to sham. Very 
limited confidence due to 1 small 





Pain: VAS, SF-MPQ, 
NRS 
Significant decrease in mean VAS score with rTMS immediately 
after treatment and at 1 month and with injection therapy 
immediately after treatment and at 1 month. Injection therapy had 
lower pain scores at baseline and 1 month compared to rTMS. 
High 
Low SOE 
TMS may be no better than sham in 
pain improvement. Limited confidence 




Significant improvements from baseline in VAS score in M1, 
DLPFC, and sham groups. Decrease in VAS significantly greater in 









Decrease in pain score (VAS) with rTMS, but not with sham. No 





Pain improved at 1 month vs baseline in both rTMS and sham 
groups on all pain measures. No significant differences between 
groups was observed. rTMS group significantly more likely to 
respond (achieve a minimum 30% improvement in pain intensity 




Pain improved after therapy (wk 14) and at 6-month follow-up for 






Pain: NRS, Headache 
symptoms 
NRS score decreased significantly in the rTMS group compared to 
placebo. 
Low Moderate SOE 
TMS probably improves headache 
pain and symptoms compared to 
sham. Limited confidence due to small 
studies with low to unclear RoB. 
Sahu, 201957 
41 
There was a greater decrease in frequency, duration, and severity 
of migraine in the active group compared to the sham group over 
the study period. 
 
Unclear 





Pain: VAS, NRS 
Decrease in pain severity at 1 wk from baseline in both groups, but 
no differences between groups. 
Unclear 
Low SOE 
TMS may improve pain compared to 
sham. Limited confidence due to 





rTMS targeted over the hand motor cortex had greater pain relief 





NRS score was not significantly different between groups at any 





Pain improvement not significantly different between the rTMS and 
sham groups during the daily sessions. No difference in number of 





S-LANSS decreased more in iTBS vs sham groups. NRS 





Percent of pain relief (%R) was greater after rTMS phase 
compared to sham phase. 54% (rTMS) vs 21% (sham) achieved 
≥30% pain relief and 35% (rTMS) vs 12% (sham) achieved ≥50% 






VAS improved significantly immediately after deep rTMS and 1-
hour after deep rTMS compared with sham. No significant pain 
improvement with rTMS immediately after or 1-hour compared with 





Pain intensity decreased from baseline to 6 wks in rTMS group and 
sham group. Pain intensity decreased more in rTMS group 










Greater proportion of responders (≥ 2 std from mean PCL) in rTMS 
groups compared to sham and no difference between bilateral and 
unilateral groups. Significant mean improvement in PCL in 






TMS may improve PTSD symptoms 
compared to sham. Limited confidence 




No difference in reduction in CAPS scores with rTMS compared 





CAPS score improved significantly in rTMS + trauma imagery 
group, but not in rTMS + positive imagery group, or sham group. 
Unclear 




Total CAPS score had a greater decrease from baseline in rTMS 




No difference in CAPS response or remission after 30 sessions. 
Improved CAPS score with 1 Hz and 10 Hz rTMS after 30 




PTSD symptoms improved at the end of treatment with 1 Hz rTMS 
compared to sham, but not with 10 Hz rTMS compared to sham. 





PTSD symptoms improved for all groups but no significant effect of 






No difference in PTSD symptoms (CAPS) between groups after 
treatment (2 wks). At 1-month (after unblinded phase) iTBS had 
greater PTSD symptom improvement compared to sham. More 
patients responded (≥ 12-point CAPS reductions) with iTBS 




All participants demonstrated significant 





rTMS group had significant reduction in PTSD symptoms 
compared with sham after treatment (2 wks). CAPS scores 
remained significantly improved from baseline at 2 months post-
treatment, but 6/10 participants had ≥ 10-point worsening in PTSD 







Overall, 47.8% of patients had clinical relapse. Fewer patients in 
active iTBS group had relapse compared to sham (OR relapse = 
3.5, 95% CI 1.04 to 11.79). 
Low Low SOE 
TMS may improve clinical relapse 
compared to sham in PTSD patients. 




Pain: Numerical rating 
scale (NRS) 
Changes in NRS over time were significantly different between 
groups. NRS score significantly lower in rTMS group compared to 
sham group at each follow-up point. 
Unclear Low SOE: 
TMS may improve pain compared to 
sham. Limited confidence due to 
single, small study with unclear RoB. 
Hoy, 201970 
21 Depressive symptoms: 
MADRS, HAM-D 
Significant improvement in depressive symptoms (MADRS) for 
both groups, but no differences between groups. 
Unclear 
Low SOE: 
TMS may improve depressive 
symptoms compared to sham. Limited Lee, 2018
71 
13 
Significant improvements in depressive symptoms after rTMS, but 
not after sham. 
Unclear 
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Rao, 201976  
35 
No statistically significant differences between groups in changes in 
HAM-D scores or on rates of remission or response. HAM-D scores 
varied widely, favoring rTMS at some time points and sham at 
others. 
Unclear confidence due to inconsistent findings 
and unclear RoB. 
Siddiqi, 201977 
15 
Mean MADRS improvement was greater with rTMS than with 






More patients in rTMS group had ≥ 50% headache reduction 
compared to sham. Composite score of debilitating headache 
exacerbation significantly reduced in rTMS group at 4 wks while 
sham did not. 
Unclear 
Low SOE: 
TMS may improve headache 
symptoms compared to sham. Limited 
confidence due to inconsistent findings 
and low to unclear RoB. 
Leung, 201873 
29 
Signification reduction in average daily persistent headache 
intensity with rTMS but not sham at 1- and 4-wks. Significant 
reduction in % of patients no longer experiencing persistent 
headaches with rTMS but not sham at 1- and 4-wks. 
Unclear 
Stilling, 202078  
20 
Significant overall time effect for average headache severity but no 
effect of treatment group at 1-month post-treatment. 
Low 
Choi, 201869 
12 Quality of Life: SF-36, 
Quality of Life 
Evaluation Scale, 
Quality of Life after 
Brain Injury 
Questionnaire 
SF-36 physical component scores increased more in rTMS group 
compared to sham group at each time point, but SF-36 mental 
component scores did not change significantly over time. 
Unclear 
Low SOE: 
Unclear whether TMS improves quality 
of life. Limited by inconsistent findings 
and low to high RoB. 
Manko, 201374 
40 
Mental and physical comfort significantly improved with rTMS 




There was a significant time effect for quality of life, but no 












Unclear if rTMS improves function 
compared to sham. Confidence limited 




No difference in Conner's Continuous Performance (CPT) at wks 1 
or 4 between groups. Significant interaction of visit and treatment at 
1 wk, with an increase in CPT score with rTMS, but decrease in 




No overall interaction between group and time on Conner's 




No differences in executive function between groups or in time x 
group interactions. rTMS group improved significantly at 90-days 




Effects on neuropsychological functioning varied and favored rTMS 
for some measures and sham for others. 
 
Unclear 






subjective 0-100 scale 
Craving scores decreased more in first 30 days in both 1 Hz and 10 
Hz groups, compared to control. All groups had significantly 




TMS may improve craving scores 
compared to sham. Limited by unclear 
RoB. Shen, 201680 
20 
Significant reduction in craving score after rTMS but not after sham 
rTMS. 
Unclear 
*defined as suicide (attempt or otherwise), inpatient psychiatric hospitalization, or need for rTMS retreatment) 
Abbreviations: iTBS=intermittent theta-burst stimulation; rTMS=repetitive transcranial magnetic stimulation; VAS=visual analog scale; NRS=numerical rating scale; PCL=PTSD 
symptom checklist; SF-MPQ=Short-Form McGill Pain Questionnaire; MADRS=Montgomery-Asberg Depression Rating Scale; HAM-D=Hamilton Depression Rating Scale; 
CAPS=Clinician administered PTSD scale; RoB=Risk of bias; S-LANSS=Leeds assessment of neuropathic symptoms and signs; SF-36=short form 36 
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PEER REVIEW COMMENTS TABLE 
Comment # Reviewer # Comment Author Response 
Are the objectives, scope, and methods for this review clearly described? 
1 1 Yes None 
2 2 Yes None 
Is there any indication of bias in our synthesis of the evidence? 
3 1 No None 
4 2 No None 
Are there any published or unpublished studies that we may have overlooked? 
5 1 No None 
6 2 Yes - This depends on the scope of TBI being discussed. Please 
see below. 
We have clarified the scope of TBI. We did not limit to any 
severity of TBI but have specified the TBI severity in the 
included studies. 
Additional suggestions or comments can be provided below. If applicable, please indicate the page and line numbers from the draft report. 
7 1 I think it would be helpful to provide more detail for each indication 
what type of TMS has been researched as a treatment for the 
indication. For instance, under each indication there is a call-out 
box with the number of studies, level of SOE, number and mean 
of of participants, and summary of findings. It might be helpful to 
include in these boxes what type of TMS were used in the studies 
for each of the indications. This would make it easier for the 
audience to see for which conditions different types of TMS have 
been explored. 
We have specified in summary statements and in the 
individual descriptions, which studies are rTMS and which 
studies are other forms of TMS. We have clarified that most 
studies are in rTMS throughout. 
8 1 I think it would also be helpful in the Summary and Discussion 
section to include more context for the results, namely that since 
rTMS was the more commonly utilized protocol of TMS, the 
results should be understood in the appropriate context. In this 
section, the authors state "TMS therapy may be effective for 
treating chronic pain, PTSD, TBI, and opiate addiction" but there 
is very little evidence to support this conclusion in the context of 
iTMS, sTMS, and MERT compared to rTMS or deep TMS. 
Another way to clarify the context might be to include another 
figure similar to figure 2 (pg 9 line 13) to show the breakdown of 
the different types of TMS included in the review, perhaps even 
broken down to show which were studied and in how many 
papers for each condition (which would also address my previous 
We have clarified throughout the report that most of the 
evidence was for rTMS. We have specified in summary 
statements and in the individual descriptions, which studies 
are rTMS and which studies are other forms of TMS. We 
have updated Figure 2 to reflect the number of studies in 
rTMS and other TMS therapies. 
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point). For each indication, broad statements that "TMS may be 
effective for x" are used but I think the context of WHICH TMS 
may be effective is important since some varieties have been 
much more thoroughly studied than others. 
9 2 The review was very well-written and I have a few suggestions for 
additional clarity for other readers. Please note that page numbers 
below refer to the PDF page number and not the page number of 
the document. 
None. 
10 2 Page 6 - line 24: It would be more accurate to mention here (as 
you do later in the document), that TMS stimulation passes 
through the scalp/skull to stimulate the brain at the cortex. 
Changed. 
11 2 Page 8 - line 59: While it is true that any stimulation above 100% 
of resting motor threshold (RMT) increases the risk for seizure. 
The typical prescription for MDD is to treat at 120% of RMT. Given 
that this is common practice, it can be confusing for readers and 
this detail should be included for completeness. 
We have added this detail for clarity. 
12 2 Page 9 - line 24-25: It is true that the FDA approves the use of a 
new technology prior before it being used to treat a specific 
condition. To the best of my knowledge, the FDA approves the 
initially proposed device. Any additional devices with similar 
evidence, etc. then must demonstrate the equivalency of their 
device and it is then "cleared" by the FDA rather than approved. 
This wording has been changed for clarity. 
13 2 Page 20 - Summary Box: I am not sure if there is a typo in this 
box or if the age range is just flipped. It is odd to read the lower 
end of the age range on the right. 
This was an error, and the end age range has been fixed. 
14 2 General comments: 
PAGE 21 - PTSD versus sexual trauma 
This is a particularly interesting differentiating as it explicitly 
suggests a couple of differing things: (1) sexual trauma is different 
from PTSD and/or (2) PTSD resultant from sexual trauma as the 
criterion A event may manifest itself in a completely different way 
than other criterion A events. Overall, this implies that the 
potential underlying neuroanatomical substrates might differ 
based on type of trauma. The literature does not necessarily 
support this, but it does suggest that there are other factors which 
are associated with the incidence of specific types of trauma. All 
this to say, it is curious as to why sexual trauma is being 
discussed as a distinct condition. 
We agree that there is the potential for these two patient 
groups to overlap. We included studies of PTSD, regardless 
of the traumatic event. Patients with sexual trauma may 
have been included in these studies, but as the traumatic 
events were not commonly reported, we do not know if, or 
how many. Since people with sexual trauma may or may not 
have a diagnosis of PTSD, and may seek treatment without 
a diagnosis of PTSD, we feel it makes sense to leave sexual 
trauma in its own category. Moreover, the legislation 
motivating the request for this review differentiates PTSD 
from sexual trauma. We have added a couple of sentences 
to the discussion section to clarify this potential overlap. 
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15 2 PAGE 22 - TBI symptoms and severity 
In order to fully elaborate on this area, it is important to indicate 
what severity level of TBI you are discussing. Is the evidence 
limited to mild to moderate TBI, or does it include information 
regarding severe TBI. Also, does the scope of the question 
include treating severe TBI resulting in minimally conscious 
persons? Reading of this gives the impression that only mild TBI 
is covered. If so, that should be explicitly stated.  
The description of symptoms treated is also vague and it is 
unclear what about TBI is being considered. Does the key 
question want to focus on cognitive sequelae, mood sequelae, 
those measured and identified on the Neurobehavioral Symptom 
Inventory (NSI). Additionally, post-concussive symptoms (PCS) 
could also be considered a separate condition in itself and has a 
variety of subsequent considerations. In sum, there is a lack of 
specificity in this area which makes this section less useful than it 
could be. 
We agree that more detail is useful in describing the results 
of the effect of TMS on TBI. We included any study that 
examined the use of TMS on TBI symptoms (any post-TBI 
symptoms and any TBI severity). We have added detail on 
TBI severity in the specific studies. We have added a 
sentence to clarify that we were looking at any post-TBI 
symptoms. 
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